NZ617500B2 - Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists - Google Patents

Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists Download PDF

Info

Publication number
NZ617500B2
NZ617500B2 NZ617500A NZ61750012A NZ617500B2 NZ 617500 B2 NZ617500 B2 NZ 617500B2 NZ 617500 A NZ617500 A NZ 617500A NZ 61750012 A NZ61750012 A NZ 61750012A NZ 617500 B2 NZ617500 B2 NZ 617500B2
Authority
NZ
New Zealand
Prior art keywords
benzyl
oxadiazolyl
phenyl
piperidinecarboxylic acid
chloroisobutyl
Prior art date
Application number
NZ617500A
Other versions
NZ617500A (en
Inventor
Jayraj D Aradhye
Isabelle Berrebibertrand
Marc Capet
Japan Nitinkumar Desai
Jeannemarie Lecomte
Ranjan Kumar Pal
Bhavesh M Panchal
Sandeep Pankajbhai Pathak
Muthukumaran Natarajan Pillai
Kaushik Dhanjubhai Prajapati
Original Assignee
Bioprojet
Sun Pharma Advanced Research Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11305433A external-priority patent/EP2511275A1/en
Application filed by Bioprojet, Sun Pharma Advanced Research Company Ltd filed Critical Bioprojet
Publication of NZ617500A publication Critical patent/NZ617500A/en
Publication of NZ617500B2 publication Critical patent/NZ617500B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Disclosed herein are the compounds of formula I which are oxadiazole piperidine carboxylic acids where the subsituents are as defined herein, an example being 1-{4-[5-(3-chloro-4-cyclohexylphenyl)-[1,2,4]-oxadiazol-3-yl]benzyl}-4-methylpiperidine-4-carboxylic acid. Also disclosed are methods of synthesis of these compounds and their use in conditions such as immune disorders, diabetes, hepatitis and cancer. hesis of these compounds and their use in conditions such as immune disorders, diabetes, hepatitis and cancer.

Description

NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS The present invention relates to novel compounds acting as agonists at S1P (sphingosinephosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation.
S1P is a bioactive sphingolipid metabolite that is intimately involved in mediating various immunological processes by its actions on S1P receptors. S1P receptor, originally termed as endothelial differentiation gene (EDG) receptor, is a family of five related G-protein coupled receptors, namely S1P1/EDG1, S1P2/EDG5, S1P3/EDG3, S1P4/EDG6 and S1P5/EDG8. These receptors have wide spread cellular and tissue distribution and are well conserved in human and rodent species.
S1P is stored and released from platelets upon their activation, but can also be synthesized in a wide variety of cell types in response to extracellular stimuli like growth factors and cytokines. It is involved in a number of cellular functions including cell growth, differentiation, migration and apoptosis and thus may have an important role in pathophysiological disease states such as atherosclerosis and cancer. S1P exerts these diverse cellular effects depending on the expression of the specific S1P receptors subtypes and its coupling to these receptors.
EDG1 receptor was the first identified S1P receptor that was initially isolated as an orphan GPCR (G protein-coupled receptor) in human endothelial cells, and it was later shown to encode a high-affinity S1P receptor. Expression of EDG1 is pervasive, including spleen, brain, heart, lung, adipose tissues, liver, thymus, kidney, and skeletal muscle. EDG5 was first isolated as an orphan GPCR gene from rat cardiovascular and nervous systems. Its expression is widespread; it is present in heart, lung, thymus, brain, liver, kidney, spleen, adipose tissues in adult mouse, and in lung, heart, stomach, intestine, and adrenal glands in rats. EDG3 was isolated as an orphan GPCR gene by degenerate PCR-based cloning from a human genomic DNA library. Like EDG5, EDG3 is a high-affinity S1P receptor. The expression of EDG3 is widespread; it is present in the spleen, heart, lung, thymus, kidney, testis, brain, and skeletal muscle in adult mice and, in humans, in the heart, placenta, kidney, liver, pancreas, skeletal muscle, lung, and brain. Unlike EDG1, EDG5 and EDG3 receptors, EDG6 expression is restricted in human and mouse to lymph node, spleen, lung, and thymus. This expression pattern suggests potential roles of EDG6 in the immune system. In vivo roles and functions of EDG6 are still unknown. In rat brain, EDG8 is predominantly expressed in white matter tracts and cells of oligodendrocyte lineage, suggesting its potential roles in maturation and myelination of oligodendrocytes. The physiological roles for EDG8 have not been found in the published literature.
EDG1 receptor mediated responses play an essential role in modulating cell trafficking between the lymphatic system and blood. EDG1 receptor agonists cause sequestration of lymphocytes in secondary lymphoid organs which is associated with clinically useful immunosuppression. Immunosuppression is desirable to prevent and/or treat rejection after organ, tissue or cell transplantation and in the treatment of autoimmune disorders. Agents acting as immunosuppressants have been shown to be useful in a variety of autoimmune and inflammatory disorders like transplant rejection, tissue graft rejection, immune disorders, auto immune disorders, autoimmune uveitis, ischemia, rheumatoid arthritis, pollinosis, multiple sclerosis, sepsis, inflammatory bowel disease, asthma, diabetes mellitus, atherosclerosis, lupus erythematosus, myocarditis, multiorgan failure, glomerulonephritis, atopic dermatitis, lymphocytic leukemias, lymphomas, Alzheimer’s disease, pneumonia, psoriasis as well as disorders related to impaired vascular integrity, cancers, disregulated angiogenesis or excessive neoangiogenesis.
Recently, FTY720 (Fingolimod), an EDG1 receptor agonist has been approved by FDA for treatment of patients with relapsing form of Multiple Sclerosis. However, there are certain studies which report FTY720 to have an adverse effect of asymptomatic bradycardia, which is reported to be due to nonselective agonism at the EDG3 receptor (Bioorg. &Med.
Chem. Lett., 2004, 14, 3501) Thus, there is a continued interest in developing S1P receptor agonists showing receptor selectivity at EDG1 receptor, specifically, compounds which show low relative activity at EDG3 receptor expressed in cardiac tissues. (Hale et al, Bioorg. Med. Chem. Lett. 14, (2004), 3501-3505). Various EDG1 agonists have been disclosed in prior art references.
For example WO2003105771 assigned to Merck discloses EDG1 agonists, which were oxadiazole compounds substituted by aryl group at the 3- and 5-positions. All the compounds disclosed in this application were either azetidinyl- or pyrrolidinyl carboxylic acids.
WO2007132307, assigned to Pfizer, discloses EDG1 receptor agonist compounds having oxadiazole ring substituted at 3- and 5- position by aryl group. All the compounds disclosed in this application were aminocycloalkyl carboxylic acids, more specifically aminocyclobutanes substituted by carboxylic acid group. WO2008152149 relates to dicarboxylic acids as EDG1 agonists.
The present invention relates to certain novel piperidine monocarboxylic acids which are effective as agonists on human S1P1 receptors. The present invention relates to a compound of formula (I): COOH wherein: Ar is an aryl group optionally substituted by one or more identical or different group(s) selected from halogen, alkyl, cycloalkyl, -Oalkyl, aryl wherein the alkyl, cycloalkyl, -Oalkyl, aryl may be further substituted with halogen, OH, Oalkyl, CN, NH , NHalkyl, Nalkyl , alkyl; R1 represents –X-(Y)n where -X- is selected from –alkyl-, -alkenyl-, -alkynyl-, -aryl-, -alkylaryl-, Each Y, identical or different is selected from H, OH, halogen, -Oalkyl, -Oalkylaryl, -OalkylOalkyl, -Oaryl, heteroaryl, -Oaryl(Oalkyl), -Ocycloalkyl, -cycloalkyl, heterocyclyl; n is 1 to 3; R2 is selected from H, alkyl; or one of its stereoisomers, salts or esters thereof.
In a preferred embodiment, the present invention relates to the compound of formula (I), wherein Ar is a Phenyl group, more preferably Ar is a disubstituted Phenyl wherein the substituents are as defined above for formula (I).
The invention also provides a process of preparation of a compound of the invention comprising saponifying a compound of formula (III) N R2 COOAlk (III) where Ar, R2, R1 are as defined above and Alk represents a C1-C6 alkyl group, optionally followed by forming the desired addition salt.
The invention also provides a process of preparation of a compound of the invention comprising reacting a compound of formula (VII): N R2 (VII) with a compound of formula (VIII) COOR (VIII) where Ar, R2, R1 are as defined above, and R may be alkyl, optionally followed by forming the desired addition salt.
The invention also provides a compound prepared by the process of the invention.
Unless specified otherwise, the terms used hereabove or hereafter have the meaning ascribed to them below: “Halo”, “hal” or “halogen” refers to fluorine, chlorine, bromine or iodine atom.
"Alkyl'' represents an aliphatic-hydrocarbon group which may be straight or branched having 1 to 20 carbon atoms in the chain unless specified otherwise. Preferred alkyl groups have 1 to 12 carbon atoms, more preferably have 1 to 8 carbon atoms in the chain, most preferably have 1 to 6 carbon atoms in the chain. In a particularly preferred embodiment the alkyl group has 1 to 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, iso-butyl, n-butyl, tert-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
"Cycloalkyl" refers to a non-aromatic mono- or polycyclic hydrocarbon ring system of 3 to 10 carbon atoms. More preferably the cycloalkyl group has of 4 to 10 carbon atoms, more preferably 4 to 8 carbon atoms and most preferably have 4 to 6 carbon atoms.
Exemplary monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Exemplary multicyclic cycloalkyl include 1-decalin, norbornyl, adamant-(1- or 2-)yl.
"Aryl" refers to an aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring system of 6 to 14 carbon atoms. More preferably aryl refers to a nonocyclic or bicyclic ring containing 6 to 10 carbon atoms. Exemplary aryl groups include phenyl, naphthyl, indenyl, phenanthryl, biphenyl. Most preferably the aryl group is Phenyl.
"Alkenyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having 2 to 15 carbon atoms in the chain unless specified otherwise. Preferred alkenyl groups have 2 to 12 carbon atoms in the chain; more preferably about 2 to 8 carbon atoms in the chain and most preferably have 2 to 4 carbon atoms in the chain. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, iso- butenyl, 3-methylbutenyl, n-pentenyl, heptenyl, octenyl, nonenyl, decenyl.
"Alkynyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having 2 to 15 carbon atoms in the chain unless specified otherwise. Preferred alkynyl groups have 2 to 12 carbon atoms in the chain; more preferably have 2 to 8 carbon atoms in the chain, most preferably have 2 to 4 carbon atoms in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, 4,4-dimethylpentynyl, heptynyl, octynyl and decynyl.
“Arylalkyl” refers to an alkyl group substituted with an aryl group. The terms “alkyl” and “aryl” are as defined above.
“-Oarylalkyl” refers to a group wherein –O is attached to an alkyl group which is substituted with an aryl group. The terms “alkyl” and “aryl” are as defined above. Exemplary “Oarylalkyl” groups include –O-CH -Phenyl.
The term "heteroaryl" refers to a 5 to 14, preferably 5 to 10 membered aromatic mono-, bi- or multicyclic ring wherein at least one member of the ring is a hetero atom such as N, O, S. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazoyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl.
The terms "heterocycle", “heterocyclyl” or "heterocyclic" refer to a saturated or partially unsaturated non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings wherein at least one member of the ring is a hetero atom, such as N, O, S.
Typically, heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms. Preferable heteroatoms are oxygen, nitrogen and sulfur. Suitable heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76th Edition, CRC Press, Inc., 1995-1996, pages 2-25 to 2-26, the disclosure of which is hereby incorporated by reference. Preferred non aromatic heterocyclic include, but are not limited to oxetanyl, tetraydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl, imidazolidinyl, pyranyl. Preferred saturated heterocycles are chosen from tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl, imidazolidinyl, more preferably tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl.
"Alkyl", "cycloalkyl", "alkenyl", "alkynyl", "aryl", etc… also refers to the corresponding divalent "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene", etc., which are formed by the removal of two hydrogen atoms.
The compounds of the present invention possess an acidic group and a basic group which may form corresponding salts. Thus the present invention includes salts of compounds of formula (I). The salts may preferably be pharmaceutically acceptable salts. The acidic group may form salts with bases. The base may be an organic amine base, for example trimethylamine, tert-butylamine, tromethamine, meglumine, epolamine, etc. The acidic group may also form salts with inorganic bases like sodium hydroxide, potassium hydroxide, etc.
The basic group may form salts with inorganic acids like hydrochloric acid, sulfuric acid, hydrobromic acid, sulfamic acid, phosphoric acid, nitric acid etc and organic acids like acetic acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, glucoronic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, oxalic acid, fumaric acid, maleic acid etc. Further, compounds of formula (I) may form quaternary ammonium salts and salts with amino acids such as arginine, lysine, etc. Lists of suitable salts may be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418 and P.H. Stahl, C.G. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley- VCH, 2002, the disclosures of which are hereby incorporated by reference.
As used herein, the term "patient" refers to a warm-blooded animal such as a mammal, preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
As used herein, a "therapeutically effective amount" refers to an amount of a compound of the present invention which is effective in reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions. The term "controlling" is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment and chronic use.
As used herein, the expression "pharmaceutically acceptable" refers to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
The term “comprising” as used in this specification means “consisting at least in part of”. When interpreting each statement in this specification that includes the term “comprising”, features other than that or those prefaced by the term may also be present.
Related terms such as “comprise” and “comprises” are to be interpreted in the same manner.
A preferred embodiment of compound of formula (I) is described herein and represented by a compound of formula (II): COOH (II) or one of its isomers, salts or esters thereof wherein: R1 is selected as in formula (I); and/or R3 is selected from halogen, C alkyl , C cycloalkyl, -O-C alkyl, aryl; More preferably R3 1-6 3-7 1-6 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, cyclopentyl, cyclohexyl, cycloheptyl, isopropoxy, phenyl. Most preferably R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl;and/or Hal represents a halogen, such as F, Cl, Br, I.
Also described is compound of formula (II) wherein R1 is selected from C alkyl, C 1-6 2-4 alkenyl, C alkynyl, aryl and arylalkyl each being optionally substituted by one or more of OH, halogen, -Oalkyl, -Oarylalkyl, -OalkylOalkyl, Oaryl, heteroaryl, -Oaryl(Oalkyl), - Ocycloalkyl, -cycloalkyl, heterocyclyl.
More preferably R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondary butyl, tertiary butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, ethoxymethyl, methoxyethyl, vinyl, allyl, methoxyethoxymethyl, ethoxyethoxymethyl, ethoxyethoxyethyl, Phenyl, benzyl, benzyloxymethyl, benzyloxyethyl, -CH-[Ph(o-F)], -CH-[Ph(m-F)], -CH-[Ph(p-F)], -CH - 2 2 2 2 [Ph(o-OMe)], -CH -[Ph(m-OMe)], -CH -[Ph(p-OMe)], methoxybutyl, methoxyethoxymethyl, - CH -[Ph(o,o-F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl, 2 2 2 3 2 2 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl-propyl.
Still more preferably, R1 is selected from methyl, ethyl, n-propyl, hydroxymethyl, methoxymethyl, allyl, methoxyethoxymethyl, Phenyl, benzyl, benzyloxymethyl, -CH -[Ph(o- F)], -CH-[Ph(p-F)], -CH-[Ph(o-OMe)], -CH-[Ph(p-OMe)], methoxybutyl, 2 2 2 methoxyethoxymethyl, -CH -[Ph(o,o-F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2- 2 2 2 3 2 2 methoxy-phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3- pyrrolidinyl-propyl. wherein, p-F, o-F, p-OMe and o-OMe stands for para-fluoro, ortho-fluoro, para- methoxy and ortho-methoxy respectively.
More preferably, described is a compound of formula (I) or (II) above, wherein: R1 is selected from –CH , -C H , -n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH - 3 2 5 3 7 2 3 2 2 2 2 CH -OCH, -Ph, -CH -O-CH-Ph, -CH-Ph, -CH-[Ph(p-F)], -CH-[Ph(o-F)], -CH -[Ph(p- 2 3 2 2 2 2 2 2 OMe)], -CH-[Ph(o-OMe)] or -CHOH, methoxybutyl, methoxyethoxymethyl, methoxyethoxyethyl, -CH -CH -O-Ph, -CH(CH ) , -CH -[Ph(o,o-F )], -CH -[Ph(m-CF )], -CH - 2 2 3 2 2 2 2 3 2 furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3- piperidinyl-propyl, 3-pyrrolidinyl-propyl. ; and/or - R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl, isopropoxy; wherein, p-F, o-F, p-OMe and o-OMe stands for para-fluoro, ortho-fluoro, para-methoxy and ortho-methoxy respectively.
Also described is a compound of formula (I) or (II) wherein when R1 is –CH , -C H , - 3 2 5 n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH -CH -OCH , -Ph, -CH -O-CH -Ph, -CH -Ph, 3 7 2 3 2 2 2 2 2 3 2 2 2 -CH-[Ph(p-F)], -CH-[Ph(o-F)], -CH-[Ph(p-OMe)], -CH-[Ph(o-OMe)], -CH OH, 2 2 2 2 2 methoxybutyl, methoxyethoxymethyl, methoxyethoxyethyl, isopropoxymethyl, -CH -CH -O- Ph, -CH(CH ) -CH -[Ph(o,o-F )], -CH -[Ph(m-CF )], -CH -furyl, -CH -pyridyl, (2-methoxy- 3 2 2 2 2 3 2 2 phenoxy)-ethyl, 4-methoxy-benzyl, isopropoxymethyl, cyclopentyloxymethyl, thiophen ylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl- propyl, then R3 is isobutyl; when R1 is –CH , -C H , -n-C H , -CH -O-CH , -CH -CH=CH , -CH -O-CH -CH -OCH , 3 2 5 3 7 2 3 2 2 2 2 2 3 -CH -O-CH -Ph, , -CH -pyridyl,, CH -[Ph(OMe)], -CH -[Ph(F)], -CH -Ph or -CH OH then R3 is 2 2 2 2 2 2 2 –Ph; when R1 is –CH , – CH CH , -CH -O-CH CH -[Ph(OMe)], then R3 is –cyclohexyl; 3 2 3 2 3 , 2 when R1 is –CH or -CH -O-CH then R3 is cyclopentyl; 3 2 3 when R1 is –CH -CH , -CH -CH=CH -CH -O-CH3 or -CH -O-CH -CH -O-CH then R3 is 2 3 2 2 , 2 2 2 2 3 isopropoxy.
Following are examples of some of the representative compounds described herein.
These examples are for illustration purposes only and should not be considered to be limiting the invention. 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidinecarboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}hydroxymethylpiperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl}methoxymethylpiperidine- 4-carboxylic acid 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}hydroxymethylpiperidine carboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine carboxylic acid 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-fluoro-benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-fluoro-benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-methoxy-benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-methoxy-benzyl)-piperidinecarboxylic acid 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidinecarboxylic acid 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-butyl)- piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy-ethyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl-piperidine carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl-piperidine carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy-phenoxy)- ethyl]-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine carboxylic acid 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine- 4-carboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine carboxylic acid 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methoxymethyl- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy-ethoxymethyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopentyloxymethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophenylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopropylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-morpholinyl-ethyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-piperidinyl-propyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-pyrrolidinyl-propyl)- piperidinecarboxylic acid or one of their isomers, salts or esters thereof.
Also described are compounds including the following: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, sodium salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, arginine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, potassium salt 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidinecarboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid, tert-butylamine salt 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid tert-butylamine salt 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidinecarboxylic acidtert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}hydroxymethylpiperidine- 4-carboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl}methoxymethylpiperidine- 4-carboxylic acid tert-butylamine salt 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}hydroxymethylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine carboxylic acid tert-butylamine salt 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine carboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-fluoro-benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-fluoro-benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-methoxy-benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-methoxy-benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-butyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid potassium salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy-ethyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl- benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy-phenoxy)- ethyl]-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine carboxylic acid tert-butyl amine salt 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine- 4-carboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)-piperidine- 4-carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl-piperidine carboxylic acid tert-butyl amine salt 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methoxymethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl-piperidine- 4-carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy-ethoxymethyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopentyloxymethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophenylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}cyclopropylmethyl- piperidinecarboxylic acid tert-butyl amine salt or one of their isomers.
Also described is the process of preparation of the compound of formula (I).
The compounds and process described herein may be prepared in a number of ways well known to those skilled in the art. The compounds can be synthesized, for example, by application or adaptation of the methods described below, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well known or readily obtainable from the scientific literature to those skilled in the art.
In particular, such methods can be found in R.C. Larock, Comprehensive Organic Transformations, VCH publishers, 1989 It will be appreciated that the compounds described herein may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare and isolate such optically active forms.
For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
Compounds described herein may be prepared by a variety of synthetic routes. The reagents and starting materials are commercially available, or readily synthesized by well- known techniques by one of ordinary skill in the arts. All substituents, unless otherwise indicated, are as previously defined.
In the reactions described hereinafter, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in Protective Groups in Organic Synthesis, John Wiley and Sons, 1991; J. F. W. McOmie in Protective Groups in Organic Chemistry, Plenum Press, 1973.
Some reactions may be carried out in the presence of a base. There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used in reactions of this type may equally be used here, provided that it has no adverse effect on other parts of the molecule. Examples of suitable bases include: sodium hydroxide, potassium carbonate, triethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
Usually, reactions are carried out in a suitable solvent. A variety of solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved.
Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethyl-formamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
The reactions can take place over a wide range of temperatures. In general, we find it convenient to carry out the reaction at a temperature of from 0°C to 150°C (more preferably from about room temperature to 100°C). The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
The compound thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well-known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
In particular, the compounds described herein may be prepared from the processes described below. The intermediates used in the processes are either commercially available or may be synthesized in the laboratory from well-known starting materials and processes.
The process of preparing the compounds of the present invention is apparent or readily obtainable from prior art references, eg. WO2003/105771, WO2008152149 According to a first embodiment, the process of preparation of a compound of formula (I) comprises saponifying a compound of formula (III): N R2 COOAlk (III) where Ar, R2, R1 are defined as in formula (I) and Alk represents an alkyl group, optionally followed by forming the desired addition salt.
The saponification reaction is generally conducted in the presence of a mineral base such as NaOH, KOH or their mixtures, preferably at a temperature comprised between the room temperature and the reflux temperature of the reaction mixture.
The addition salt is generally obtained by reacting the formed acid with a base corresponding to the desired addition salt. The added base can be organic including amines, such as tert-butylamine, or inorganic bases such as NaOH, KOH, etc.
Following addition of the base, the compound of formula (I) is generally in the form of the carboxylate salt, where the counter ion is the cation resulting from the addition of a proton to the base.
The acid form of the compound of formula (I) may be recovered from its base addition salt by acidifying said salt.
The compound of formula (III) may be obtained by coupling a compound of formula (IV): (IV) with a corresponding compound of formula (V): COOAlk where Ar, R2, R1 are defined as in formula (I), Alk is defined as in formula (III) and LG is a leaving group such as a halogen atom, preferably Cl or the mesylate (O-SO2-CH3) group.
This reaction is generally conducted in the presence of a base. Where LG is a halogen atom, the base may be potassium carbonate to neutralize the formed acid.
When LG is mesylate the base may be organic, preferably N,N-diisopropylethylamine, triethyl amine or inorganic, preferably potassium, cesium or sodium carbonate.
Preferably, the reaction is conducted at a temperature comprised between the room temperature and the reflux temperature of the reaction mixture.
The compound of formula (IV) wherein LG is a halide or mesylate may be obtained by converting a compound of formula (VI): N R2 (VI) where Ar and R2 are defined as in formula (I) into the desired halide or mesylate.
The substitution reaction may be conducted by reacting said compound of formula (VI) with usual halogenating agents such as thionyl halogenide, hydrohalogenide acid H-Hal, phosphorus trihalogenide, etc., preferably thionyl chloride. Alternatively, the mesylate derivative may be obtained by reacting said compound (VI) with mesyl chloride, in the presence of a base such as a tertiary amine, in particular triethylamine or an inorganic base, such as carbonate, hydrogenocarbonate.
According to a second embodiment, the compound of formula (I) may be obtained by reacting a compound of formula (VII): N R2 (VII) with a compound of formula (VIII): COOR (VIII) where Ar, R2, R1 are defined as in formula (I) and R may be H or alkyl, optionally followed by forming the desired addition salt.
This reaction is generally carried out in acidic medium (such as in the presence of acetic acid), followed by the addition of a reductive agent such as sodium cyanoborohydride.
If a base addition salt of the compound of formula (I) is desired, this reaction may be followed by the addition of a base, as discussed above.
The compound of formula (VII) may be obtained by oxidizing a compound of formula (VI): (VI) where Ar and R2 are defined as in formula (I). This reaction may be carried out in known conditions generally used for oxidizing primary or secondary alcohol, as the case may be. In particular, this reaction may be conducted in the presence of pyridinium chlorochromate (PCC).
The compound of formula (VI) used in both embodiments above may be obtained by (a) reacting a compound of formula (IX): (IX) where Ar is defined as in formula (I) with N-hydroxyhydroxymethylbenzamidine, optionally in the presence of one or more of activating and/or coupling agent, such as N,N’-Dicyclohexylcarbodiimide (DCC) and N-hydroxybenzotriazole monohydrate (HOBt), so as to form a compound of formula (VI) where R2 is H, and optionally followed when a compound (VI) where R2 is alkyl is desired by (b) oxidizing the compound of formula (VI) (wherein R2 is H) followed by its reaction with alkylmagnesiumhalide.
The process described herein may also include the additional step of isolating the obtained compounds.
The compounds of formula (IX), (VII), (VIII), (V) and N-hydroxy hydroxymethylbenzamidine are commercially available or may be synthesized by applying or adapting known procedures.
The compounds of formula (VI): N R2 (VI) wherein Ar and R2 are defined as in formula (II), where R2 is selected from H, alkyl and Ar represents a group of formula: wherein Hal represents a Cl atom and R3 is selected from halogen, aryl, cycloalkyl, alkyl are novel and are another object of the present disclosure.
In particular, in formula (X) R3 is selected from cycloalkyl such as cyclohexyl or cyclopentyl; alkyl such as iso-butyl; or aryl such as phenyl.
The salts of described herein can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two and such methods are within the level of a skilled person.
Also described are the isomers of the compounds of formula (I). The isomers can be prepared by separation of the corresponding racemic compounds by methods well known in the art.
Also described are esters of compound of formula (I). These may be prepared by methods well known to a person of skill in the art. For example, the esters may be prepared by the reaction of an acid with alcohol of the desired ester. For example, the compounds of formula (I) with a –COOH group may be reacted with methanol to form methyl ester of compound of formula (I). Similarly, ethyl, propyl, isobutyl and other esters can be prepared The compounds described herein may be useful for the treatment and/or prevention of conditions associated with S1P1/EDG1 receptor or where decrease in lymphocytes circulating in blood is desired, which include immune mediated diseases and conditions or inflammatory diseases and conditions.
The compounds described herein are suitable as immunosuppressive/ immunodepressive agents. These compounds are suitable for the treatment and/or prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis, atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired vascular integrity, cancer, or other disorders. The compounds of the present invention are generally selective EDG1 receptor agonists with very low affinity for EDG3 receptor. The selective agonism of EDG1 over EDG3 is desirable in view of the bradycardia caused by the nonselective agonism at EDG3 receptor. Also the compounds of the inventioin have low affinity for hERG channel due to which they exhibit a better side effect profile.
The compounds described herein may be used in combination with other immunomodulators or immunosuppressants including adrenocortical steroids, cyclosporine, azathioprine, methotrexate, calcineurin inhibitors, IL-2 receptor blocking antibodies, T-cell depleting antibodies, anti-TNF, mycophenolate, mTOR inhibitors. Said combinations are another object of the present invention.
A typical dose range for use according to the present disclosure may be from 1 µg/kg to 0.1 g/kg of body weight per day; a preferred dose range may be from 3 µg/kg to 1 mg/kg of body weight per day. The most potent compounds could even be administered only two to three times per week at typical dosages of 10 to 100 µg/kg. Daily dose for adult humans includes 0.1 to 10 mg which can be optimized.
The dosage of drug to be administered depends on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound, excipients , and its route of administration.
The compounds described herein may be formulated into a pharmaceutically acceptable preparation, on admixing with a carrier, excipient or a diluent, in particular for oral or parenteral use. Certain preferred compounds display good oral bioavailability and are thus well suited for preparing formulations for oral use. Such preparations may be in the form of tablets, capsules or parenterals. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. Liquid carriers can include water, an organic solvent, a mixture of both or pharmaceutically acceptable oils and fats. The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A . R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. Pharmaceutically compatible binding agents and/or adjuvant materials can be included as part of the composition.
The tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule. In addition, dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents. Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings. In addition, the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
Preferred formulations include pharmaceutical compositions in which a compound described herein is formulated for oral or parenteral administration, or more preferably those in which a compound of the present invention is formulated as a tablet. Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination. It is also an aspect of the present disclosure that a compound of the present invention may be incorporated into a food product or a liquid.
Liquid preparations for administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like. Non- aqueous solvents include alcohols, propylene glycol, polyethylene glycol, acrylate copolymers, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
Aqueous carriers include mixtures of alcohols and water, hydrogels, buffered media, and saline. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds. Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
Alternative modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylenelauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations. Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
Alternative administrations include also solutions, ointments or other formulations acceptable for ocular administration.
According to a particular aspect, the compound described herein may be administered by the cutaneous, ocular or inhalation route as disclosed above. These formulations are particularly advantageous as they ensure a local treatment, without associated lymphopenia which may occur with systemic administration routes.
Other features of the invention will become apparent in the course of the following description of exemplary embodiments that are given for illustration of the invention and not intended to be limiting thereof.
The above mentioned features of the invention are given for illustration of the invention and not intended to be limiting thereof.
Preparation of intermediates I) Preparation of 3-chlorocyclohexylbenzoic acid Step (a) Anhydrous aluminium chloride (1.65 g, 0.012 mol) is added to a solution of cyclohexyl benzene (1 g, 0.006 mol) and acetyl chloride (0.7 mL, 0.009 mol) in dichloroethane (10 mL) at -5°C to 0°C temperature. The reaction mixture is stirred at this temperature for 30 minutes and then treated with 2N hydrochloric acid (7 mL). It is extracted with dichloromethane (2x20 mL) and the combined extract is dried over sodium sulfate. After removing the solvent under reduced pressure the residue is purified by column chromatography (silica gel, 230-400 mesh, ethyl acetate:n-hexane 7:93) to get 1-(4-cyclohexylphenyl)ethanone.
Step (b) A mixture of concentrated sulfuric acid & nitric acid (68-72%) (1.7:6, 15 mL) is added drop wise to a cold solution of 1-(4-cyclohexylphenyl)ethanone (6 g, 0.03 mol) in concentrated sulfuric acid (15 mL) at 0-5°C. Reaction mixture is allowed to stir at this temperature for 30 minutes & is then poured into crushed ice. It is then extracted with ethyl acetate (3x40 mL). Combined organic layer is dried over sodium sulfate and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, 230- 400 mesh, ethyl acetate:n-hexane 1:9) to yield 1-(4-cyclohexylnitrophenyl)ethanone.
Step (c) NO NH Stannous chloride dihydrate (15.8 g, 0.07 mol) is added to a solution of 1-(4- cyclohexylnitrophenyl)ethanone (5.8 g , 0.0235 mol) in concentrated hydrochloric acid (35 mL) at 0-5°C. The reaction mixture is slowly brought to 60-65°C and is stirred at this temperature for 15 minutes. After cooling to room temperature the reaction mixture is extracted with ethyl acetate (3x100 mL). The pH is adjusted to 8.0 - 9.0 using solid sodium bicarbonate. After washing with water (1x15 mL) the organic layer is dried over sodium sulfate and concentrated under reduced pressure to yield the crude, which is purified by column chromatography (230-400 mesh; ethyl acetate:n-hexane, 3:7) to give 1-(3-amino cyclohexylphenyl)ethanone.
Step (d) NH Cl Solution of sodium nitrite (1.2 g, 0.017 mol) in demineralized water (7 mL) is added to a solution of 1-(3-aminocyclohexylphenyl)ethanone (3.4 g, 0.016 mol) in concentrated hydrochloric acid (34 mL) at 0-5°C & is allowed to stir for 15 minutes at this temperature. It is then poured into a slurry of cuprous chloride (3.1 g, 0.03 mol) in demineralized water (10 mL) at 60-65°C & stirred for 30 minutes. The reaction mixture is extracted in ethyl acetate (2x30 mL). Combined organic layer is dried over sodium sulfate and concentrated to get the crude, which is purified using column chromatography (230-400 mesh; toluene:n-hexane, 3:2) to yield 1-(3-chlorocyclohexyl-phenyl)ethanone.
Step (e) Cl Cl An aqueous alkaline solution of potassium permanganate (2.94 g, 0.0186 mol; in 22 mL 12% aqueous sodium hydroxide) is added to solution of 1-(3-chloro cyclohexylphenyl)ethanone (2.2 g, 0.0093 mol) in dioxane (11 mL). The reaction mixture is stirred at 80°C temperature for 2 hrs. It is then filtered and the filtrate is washed with diethyl ether (2x10 mL). The pH of the aqueous layer is adjusted to1-2 by using 6N hydrochloric acid. It is extracted in ethyl acetate (3x15 mL). Combined organic layer is dried over sodium sulfate and concentrated to get the crude, which is purified using column chromatography (230-400 mesh; ethyl acetate:n-hexane, 1:3) to yield 3-chlorocyclohexyl benzoic acid.
II) Preparation of 3-chlorocyclopentylbenzoic acid This compound is prepared in the same way as mentioned for 3-chlorocyclohexyl benzoic acid (I).
III) Preparation of 3-chloroisobutylbenzoic acid Step (a) 4-Isobutyl benzaldehyde (7 g, 0.0431 mol) is added drop wise to a mixture of concentrated sulfuric acid & nitric acid (68-72%) (9:1, 60 mL) at 0-5°C. Reaction mixture is allowed to stir at this temperature for 2 hrs, then poured into crushed ice. It is then extracted with ethyl acetate (3x40 mL). Combined organic layer is dried over sodium sulfate and concentrated under reduced pressure. The residue is purified by column chromatography (silica gel, 230-400 mesh, ethyl acetate:n-hexane 1:19) to yield 4-isobutyl nitrobenzaldehyde.
Step (b) NO Cl 4-Isobutylnitrobenzaldehyde (3.3 g, 0.0159 mol) is added to a solution of stannous chloride (8.37 g, 0.0441 mol) in concentrated hydrochloric acid (23 mL) at 0-5°C. The reaction mixture is slowly brought to 60-65 C and is stirred at this temperature for 30 minutes.
The reaction mixture is again cooled to 0-5°C. During cooling formation of solid is observed which is broken before proceeding further. Solution of sodium nitrite (1.36 g, 0.0188 mol) in demineralized water (3 mL) is added to the above reaction mixture at 0-5 C, allowed to stir for 10 minutes at this temperature. It is then poured into a slurry of cuprous chloride (3.6 g, 0.0346 mol) in demineralized water (5 mL) at 60-65 C & stirred for 20 minutes. The reaction mixture is extracted in ethyl acetate (2x30 mL). Combined organic layer is dried over sodium sulfate and concentrated to get the crude, which is purified using column chromatography (230-400 mesh; toluene:n-hexane, 3:7) to yield 3-chloroisobutylbenzaldehyde.
Step (c) Cl Cl A mixture of sodium chlorite (80% assay, 1.06 g, 0.0094 mol) and sodium dihydrogenphosphate dihydrate (3.33 g, 0.0213 mol) in demineralized water (10 mL) is added in two equal lots (one hr interval) to a solution of 3-chloroisobutylbenzaldehyde (0.7 g, 0.0036 mol) in tert-butanol (10 mL) at room temperature. After completion of addition, stirring at room temperature is continued for 4 hrs. It is then extracted in ethyl acetate (2x30 mL).
Combined organic layer is dried over sodium sulfate and concentrated under reduced pressure to give 3-chloroisobutylbenzoic acid.
IV) Preparation of 2-chlorobiphenylcarboxylic acid Step (a) Isobutyl nitrite (121 g, 1.17 mol) and cupric chloride (21.2 g, 0.16 mol) are added to a solution of 4-bromochloroaniline (200 g, 0.97 mol) in benzene (500 mL) at 60-65 C temperature. The reaction mixture is refluxed for 2 hrs. The reaction mixture is cooled to 50- 55 C temperature and to it a solution of aqueous sulfuric acid (92 mL conc. Sulfuric acid in 453 mL demineralized water). After refluxing for 1 hr the reaction mixture is cooled to room temperature and organic layer is separated. It is treated with an aqueous solution of urea (41g in 127 mL water) and refluxed for 1 hr. Organic layer is separated, washed with demineralized water (2x200 mL) and dried over sodium sulfate. After removing the solvent under reduced pressure the residue is fractionally distilled to get 4-bromochlorobiphenyl.
Step (b) Few crystals of iodine are added to tetrahydrofuran (200 mL) containing magnesium turnings (2.8 g, 0.117 mol). The mixture is heated at 60-70C. A solution of 4-bromo chlorobiphenyl (26 g, 0.097 mol) in tetrahydrofuran (50 mL) is added dropwise to the reaction mixture and refluxed for 1hr. Reaction mixture is brought to room temperature and then cooled to -20°C. Carbon dioxide gas is passed through the reaction mixture for 45 minutes.
The reaction mixture is treated with 3N HCl (125 mL) and extracted with ethyl acetate (2x200 mL). Combined organic layer is dried over sodium sulphate. Removal of solvent under reduced pressure gives a solid which is washed with diethyl ether (2x100 mL) and then dried to furnish 2-chlorobiphenylcarboxylic acid.
V) Preparation of 4-methylpiperidinecarboxylic acid ethyl ester Step (a) n-Butyllithium (15% solution in n-hexane; 82 mL, 0.19 mol) is added to a stirred solution of diisopropyl amine (28.75 mL, 0.20 mol ) in tetrahydrofuran (400 mL) at -70°C under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4- dicarboxylic acidtert-butyl ester 4-ethyl ester (30 g, 0.12 mol) in tetrahydrofuran (80 mL) is introduced at -70°C. Hexamethyl phosphoramide (45 mL) is added and reaction mixture is allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, methyl iodide (39.3 mL, 0.60 mol) is added and stirred for 1 hour. Saturated aqueous solution of ammonium chloride (100 mL) is added slowly into the reaction mixture at 0°C and stirred for 10 minutes. It is extracted with ethyl acetate (3x200 mL). Combined organic layer is washed with brine solution (1x100 mL) and dried over sodium sulfate. Removal of solvent under reduced pressure gives a viscous liquid which is purified by column chromatography (silica gel 230-400, n-hexane:ethyl acetate, 9:1) to furnish 4-methyl piperidine-1,4- dicarboxylic acidtert-butylesterethyl ester.
Step (b) O HN A solution of hydrochloric acid (12N, 12.5 mL) in dioxane (25 mL) is added to 4-methyl piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (7.5 g, 0.028 mol) and stirred at room temperature for 1 hr. The reaction mixture is concentrated under reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with dichloromethane. After drying over sodium sulfate solvent is removed to get the crude residue which is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:ammonium hydroxide 14:85:1) to get 4-methylpiperidine carboxylic acid ethyl ester.
Following compounds, VI to XIV (except IX), can be prepared by following a process similar to compound V.
VI) 4-Ethylpiperidinecarboxylic acid ethyl ester VII) 4-(2-Methoxyethoxymethyl)piperidinecarboxylic acid ethyl ester VIII) 4-Methoxymethylpiperidinecarboxylic acid ethyl ester IX) 4-Phenyl-piperidinecarboxylic acid ethyl ester This material is commercially available.
X) 4-Benzyl-piperidinecarboxylic acid ethyl ester XI) 4-(4-Fluoro-benzyl)-piperidinecarboxylic acid ethyl ester XII) 4-(2-Fluoro-benzyl)-piperidinecarboxylic acid ethyl ester XIII) 4-(4-Methoxy-benzyl)-piperidinecarboxylic acid ethyl ester XIV) 4-(2-Methoxy-benzyl)-piperidinecarboxylic acid ethyl ester XV) Preparation of 4-allylpiperidinecarboxylic acid ethyl ester Step (a) n-Butyllithium (15% solution in n-hexane; 24.5 mL, 0.057 mol) is added to a stirred solution of diisopropyl amine (8.38 mL, 0.059 mol ) in tetrahydrofuran (140 mL) at -70°C under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4- dicarboxylic acidtert-butyl esterethyl ester (8.0 g, 0.0311 mol) in tetrahydrofuran (20 mL) is introduced at -70°C. Hexamethyl phosphoramide (15 mL) is added and reaction mixture is allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, allyl bromide (13.5 mL, 0.155 mol) is added and stirred for 1 hour. Saturated aqueous solution of ammonium chloride (100 mL) is added slowly into the reaction mixture at -30°C and stirred for 10 minutes. It is extracted with ethyl acetate (3x60 mL).Combined organic layer is washed with brine solution (1x30 mL) and dried over sodium sulfate.
Removal of solvent under reduced pressure gives a viscous liquid which is purified by column chromatography (silica gel 230-400, n-hexane:ethyl acetate, 9:1) to furnish 4-allyl piperidine- 1,4-dicarboxylic acidtert- butylesterethyl ester.
Step (b) O HN A solution of hydrochloric acid (12N, 4 mL) in dioxane (6 mL) is added to 4-allyl piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (2 g, 0.006 mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with dichloromethane. After drying over sodium sulfate solvent is removed to get 4-allylpiperidine- 4-carboxylic acid ethyl ester.
XVI) Preparation of 4-propylpiperidinecarboxylic acid ethyl ester Step (a) O N O N % Pd/C (0.6 g, 50% wet) is added to a stirred solution of 4-allylpiperidine-1,4- dicarboxylicacidtert-butylesterethyl ester (2.1 g, 0.007 mol) in ethanol (20 mL).
Hydrogen gas is bubbled through the reaction mixture at room temperature for 20 minutes.
Reaction mixture is filtered through celite bed and washed with methanol (3x5 mL).
Combined filtrate is concentrated under reduced pressure to give 4-propylpiperidine-1,4- dicarboxylic acidtert-butyl ester- 4-ethyl ester.
Step (b) O HN A solution of hydrochloric acid (12N, 4.2 mL) in dioxane (6.8 mL) is added to 4- propylpiperidine-1,4-dicarboxylic acidtert-butyl ester- 4-ethyl ester (2.2 g, 0.0073 mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with dichloromethane. After drying over sodium sulfate solvent is removed to get 4- propylpiperidinecarboxylic acid ethyl ester.
XVII) Preparation of 4-benzyloxymethyl-piperidinecarboxylic acid ethyl ester Step (a) n-Butyllithium (15% solution in n-hexane; 9.5 mL, 0.022 mol) is added to a stirred solution of diisopropyl amine (3.1 mL, 0.022 mol ) in tetrahydrofuran (15 mL) at -70°C under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-dicarboxylic acidtert butyl esterethyl ester (3 g, 0.012 mol) in tetrahydrofuran (10 mL) is introduced at -70°C. Hexamethyl phosphoramide (4.8 mL) is added and reaction mixture is allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, benzyl chloromethyl ether (5 mL, 0.035 mol) is added and stirred for 1 hour. Saturated aqueous solution of ammonium chloride (30 mL) is added slowly into the reaction mixture at -30°C and stirred for 10 minutes. It is extracted with ethyl acetate (2x20 mL). Combined organic layer is dried over sodium sulfate. Removal of solvent under reduced pressure gives a viscous liquid which is purified by column chromatography (silica gel 230-400, toluene:ethyl acetate, 23:2 to furnish 4-benzyloxymethylpiperidine-1,4-dicarboxylic acidtert butyl esterethyl ester.
Step (b) A solution of hydrochloric acid (12N, 1.5 mL) in dioxane (7.5 mL) is added to 4- benzyloxymethylpiperidine-1,4-dicarboxylic acidtert butyl esterethyl ester (1.9 g, 0.005 mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with dichloromethane. After drying over sodium sulfate solvent is removed to get 4-benzyloxymethylpiperidinecarboxylic acid ethyl ester.
XVIII) Preparation of 4-hydroxymethylpiperidinecarboxylic acid ethyl ester Step (a) n-Butyllithium (15% solution in n-hexane; 9.5 mL, 0.022 mol) is added to a stirred solution of diisopropyl amine (3.1 mL, 0.022 mol ) in tetrahydrofuran (15 mL) at -70°C under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (3 g, 0.012 mol) in tetrahydrofuran (10 mL) is introduced at -70°C. Hexamethyl phosphoramide (4.8 mL) is added and reaction mixture is allowed to stir till the temperature reaches at -45°C. Reaction mixture again cooled to -70°C, benzyl chloromethyl ether (5 mL, 0.035 mol) is added and stirred for 1 hour. Saturated aqueous solution of ammonium chloride (30 mL) is added slowly into the reaction mixture at -30°C and stirred for 10 minutes. It is extracted with ethyl acetate (2x20 mL). Combined organic layer is dried over sodium sulfate. Removal of solvent under reduced pressure gives a viscous liquid which is purified by column chromatography (silica gel 230-400, toluene:ethyl acetate, 23:2 to furnish 4-benzyloxymethylpiperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester.
Step (b) % Pd/C (1.85 g, 50% wet) is added to a solution of 4-benzyloxymethylpiperidine-1,4- dicarboxylic acidtert-butyl ester ethyl ester (1.85 g, 0.0049 m0l) in ethanol (20 mL). The reaction mixture is stirred under the positive pressure of hydrogen gas for 16 hrs at room temperature. The reaction mixture is filtered through celite bed and washed with a solution methanol and dichloromethane (1:5, 100 mL). Combine filtrate is concentrated under reduced pressure to give 4-hydroxymethylpiperidine-1,4-dicarboxylic acid 1-tert- butyl ester- 4-ethyl ester.
Step (c) O HN A solution of hydrochloric acid (12N, 2.5 mL) in dioxane (4.5 mL) is added to 4- hydroxymethylpiperidine-1,4-dicarboxylic acidtert- butyl esterethyl ester (1.35 g, 0.0047 mol) and stirred at room temperature for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is treated with aqueous solution of sodium bicarbonate to adjust the pH to 8 - 9. It is again concentrated under reduced pressure and the residue is treated with dichloromethane. After drying over sodium sulfate solvent is removed to get 4-hydroxymethylpiperidinecarboxylic acid ethyl ester.
Following intermediates XIX to XXIX can be prepared following the same procedure as that of intermediate V XIX) 4-(4-Methoxy-butyl)-piperidinecarboxylic acid ethyl ester XX) 4-(2-Phenoxy-ethyl)-piperidinecarboxylic acid ethyl ester XXI) 4-(2,6-Difluoro-benzyl)-piperidinecarboxylic acid ethyl ester XXII) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester XXIII) 4-[2-(2-Methoxy-phenoxy)-ethyl]-piperidinecarboxylic acid ethyl ester XXIV) 4-(4-Methyl-benzyl)-piperidinecarboxylic acid ethyl ester XXV) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester XXVI) 4-Pyridinylmethyl-piperidinecarboxylic acid ethyl ester XXVII) 4-Isopropoxymethyl-piperidinecarboxylic acid ethyl ester XXVIII) 4-Cyclopentyloxymethyl-piperidinecarboxylic acid ethyl ester XXIX) 4-(2-Morpholinyl-ethyl)-piperidinecarboxylic acid ethyl ester XXX) 4-Isobutylpiperidinecarboxylic acid Step (a) This compound is prepared by following a process same as that of 4- methylpiperidine-1,4-dicarboxylic acid tert-butyl esterethyl ester [step (a) of intermediate Step (b) % Pd/C (0.3 g, 50% wet) is added to a solution of 4-(2-methylallyl)piperidine-1,4- dicarboxylic acidtert-butyl esterethyl ester (1.0 g, 0.0032 mol) in ethanol (10 mL). The reaction mixture is stirred under the positive pressure of hydrogen gas for 1 hr at room temperature. The reaction mixture is filtered through celite bed and washed with ethanol (15 mL). Combine filtrate is concentrated under reduced pressure to get 4-isobutylpiperidine-1,4- dicarboxylic acidtert-butyl esterethyl ester.
Step (c) A solution of potassium hydroxide (85% assay, 2.69 g, 0.041 mol) and sodium hydroxide (1.94 g, 0.048 mol) in demineralized water (8 mL) is added to a solution of 4- isobutylpiperidine-1,4-dicarboxylic acidtertbutyl esterethyl ester (0.95 g, 0.003 mol) in ethanol (15 mL). The reaction mixture is refluxed for 48 hrs. It is cooled to room temperature, concentrated under reduced pressure, and then treated with demineralized water (10 mL).
The pH is adjusted to ~ 3-4 using 2N HCl (10 mL) and the aqueous layer is extracted with ethyl acetate (2x15 mL). The combined extract is dried over sodium sulfate. Removal of solvent gives a crude residue which is purified by column chromatography (230-400 mesh, ethyl acetate:n-hexane 1:3) to furnish 4-isobutylpiperidine-1,4-dicarboxylic acid monotertbutyl ester.
Step (d) A solution of hydrochloric acid (12N, 1.2 mL) in 1,4-dioxane (2.4 mL) is added to 4- isobutylpiperidine-1,4-dicarboxylic acid monotertbutyl ester (0.7 g, 0.0025 mol) and stirred at room temperature for 1 hr. The reaction mixture is concentrated under reduced pressure and the residue is treated with saturated solution of sodium bicarbonate (0.5 mL) to adjust the pH to ~ 7. It is again concentrate under reduced pressure to get crude 4-isobutylpiperidine carboxylic acid.
XXXI) 4-Cyclopropylmethyl-piperidinecarboxylic acid Step (a) O O N This compound is prepared following the same procedure as that of 4- methylpiperidine-1,4-dicarboxylic acid tert-butyl esterethyl ester [step (a) of intermediate Step (b) Potassium hydroxide powder (85% assay, 2.16 gm, 0.0327 mol) and 18-crown-6 ether (350 mg) are added to a solution of 4-cyclopropylmethylpiperidine-1,4-dicarboxylic acid- 1-tertbutyl esterethyl ester (1.2 gm, 0.0039 mol) in dry toluene (15 mL). The reaction mixture is refluxed for 30 minutes. It is then treated with demineralized water (15 mL) at room temperature and pH is adjusted to ~ 3- 4 using 2N HCl (20 mL). The aqueous layer is extracted with ethyl acetate (2x15 mL) and the combined extract is dried over sodium sulfate.
Removal of solvent gives 4-cyclopropylmethylpiperidine-1,4-dicarboxylic acid monotertbutyl ester.
Step (c) This intermediate is prepared following the same procedure as that of 4-isobutylpiperidinecarboxylic acid [step (d) of intermediate XXX].
XXXII) 4-Isopropyl-piperidinecarboxylic acid This intermediate is prepared following the same procedure as that of 4- cyclopropylmethyl-piperidinecarboxylic acid (XXXI).
XXXIII) 4-Thiophenylmethylpiperidinecarboxylic acid ethyl ester Step (a) Methanesulphonyl chloride (6.2 mL, 0.0797 mol) is added dropwise to a solution of thiophenemethanol (7.0 g, 0.0613 mol) and triethyl amine (12.8 mL, 0.0920 mol) in dichloromethane (70 mL) at 0-5C. The reaction mixture is allowed to stir at room temperature for 30 min. Demineralized water (25 mL) is added to the reaction mixture and the organic layer is separated. The aqueous layer is extracted with dichloromethane (1 x 25 mL). Combined organic layer is dried over anhydrous sodium sulfate. Removal of solvent under reduced pressure gives methanesulfonic acid thiophenylmethyl ester. n-Butyllithium (15% solution in n-hexane; 10 mL, 0.023 mol) is added to a stirred solution of diisopropyl amine (3.5 mL, 0.025 mol) in tetrahydrofuran (25 mL) at -70 C under an atmosphere of nitrogen and stirred for 30 minutes. A solution of piperdine-1,4-dicarboxylic acidtert-butyl esterethyl ester (3 gm, 0.012 mol) in tetrahydrofuran (10 mL) is introduced at -70 C. Hexamethyl phospharamide (4.8 mL) is added and reaction mixture is allowed to stir till the temperature reaches at -45 C. Reaction mixture is again cooled to -70 C, methanesulfonic acid thiophenylmethyl ester (5.8 gm, 0.030 mol) in tetrahydrofuran (10 mL) is added and stirred for 45 minutes. Demineralized water (15 mL) is added slowly into the reaction mixture at 0 C and stirred for 10 minutes. It is extracted with ethyl acetate (2x15 mL). Combined organic layer is dried over sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is purified by column chromatography (230-400 mesh, ethyl acetate:n-hexane 15:85) to furnish 4-thiophenylmethylpiperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester.
Step (b) This intermediate is prepared by following the same procedure as that of 4- methylpiperidinecarboxylic acid ethyl ester [step (b) of intermediate V].
XXXIV) 4-Furanylmethyl-piperidinecarboxylic acid ethyl ester This intermediate is prepared following the same procedure as that of 4-thiophen ylmethylpiperidinecarboxylic acid ethyl ester (XXXIII).
XXXV) 4-(3-Piperidinyl-propyl)-piperidinecarboxylic acid ethyl ester Step (a) This compound is prepared following the same procedure as that of 4- benzyloxymethylpiperidine-1,4-dicarboxylic acidtert-butyl ester ethyl ester [step (a) of intermediate (XVIII)].
Step (b) This compound is prepared following the same procedure as that of 4- hydroxymethylpiperidine-1,4-dicarboxylic acid 1-tert-butyl esterethyl ester [step (b) of intermediate (XVIII)].
Step (c) Carbon tetrabromide (1.6 gm, 0.0048 mol) is added to a stirred solution of 4-(3- hydroxypropyl) piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (1.27 gm, 0.0040 mol) and triphenyl phosphine (1.6 gm, 0.0060 mol) in dichloromethane (15 mL) at 0- C temperature. Reaction mixture is allowed to stir at room temperature for 30 minutes.
Removal of solvent gives a crude residue which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:n-hexane 3:7) to get 4-(3-bromopropyl)piperidine-1,4- dicarboxylic acidtert-butyl esterethyl ester.
Step (d) Piperidine (0.13 mL, 0.00132 mol) is added to a solution of 4-(3- bromopropyl)piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester (0.1 gm, 0.00026 mol) in tetrahydrofuran (5 mL). The reaction mixture is heated at 60-65 C for 3 hours. It is then cooled to room temperature, treated with demineralized water (12 mL) and extracted with ethyl acetate (2x20 mL). Combined extract is dried over sodium sulphate and concentrated under reduced pressure to get a crude residue which is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane, 1:9) to yield 4-(3- piperidinyl propyl)piperidine-1,4-dicarboxylic acidtert-butyl esterethyl ester.
Step (e) This intermediate is prepared following the same procedure as that of 4- hydroxymethylpiperidinecarboxylic acid ethyl ester [step (c) of intermediate (XVIII)].
XXXVI) 4-(3-Pyrrolidinyl-propyl)-piperidinecarboxylic acid ethyl ester This intermediate is prepared following the same procedure as that of 4-(3-piperidin- 1-yl-propyl)-piperidinecarboxylic acid ethyl ester (XXXV).
PREPARATION OF COMPOUNDS OF INVENTION The process for preparation of some of the representative compounds of the present invention are mentioned herein below. Such disclosures are simply for illustrative purposes and should not be considered as limiting the invention.
Example 1: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid Step (a) Cl Cl OH O N N,N’-Dicyclohexylcarbodiimide (0.615 g, 0.003 mol) is added to a solution of 3-chloro- 4-cyclohexyl benzoic acid (0.475 g, 0.002 mol), N-hydroxyhydroxymethylbenzamidine (0.45 g, 0.003 mol) and N-hydroxybenzotriazole monohydrate (0.457 g, 0.003 mol) in N,N- dimethylformamide (10 mL). The reaction mixture is stirred at 130-135°C for 2 hrs. It is then cooled to 0-5°C, filtered and washed with dichloromethane (2x20 mL). The filtrate is evaporated under reduced pressure and the residue is treated with demineralized water (20 mL). It is extracted with ethyl acetate (3x15 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 15:85) to give {4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]phenyl}methanol.
Step (b) Cl Cl OH Cl O N O N Thionyl chloride (0.27 mL, 0.0037 mol) and N,N-dimethylformamide (0.1 mL) are added to a stirred solution of {4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazol yl]phenyl}methanol (0.45 g, 0.0012 mol) in dichloromethane (10 mL) at 0°C. The reaction mixture is heated at 40-45°C and is stirred at this temperature for 1 hr. It is then cooled to 0- C temperature, treated with demineralized water (3 mL) and is neutralized with 4N sodium hydroxide solution at 0-5°C to adjust the pH 8-9. Finally it is extracted with dichloromethane (2x10 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives 5-(3-chlorocyclohexylphenyl)(4-chloromethylphenyl)-[1,2,4]- oxadiazole.
Step (c) Potassium carbonate (0.16 g, 0.0012 mol) and 4-methylpiperidinecarboxylic acid ethyl ester (0.21 g, 0.0012 mol) are added to a solution of 5-(3-chlorocyclohexylphenyl) (4-chloromethylphenyl)-[1,2,4]-oxadiazole (0.3 g, 0.00077 mol) in N,N-dimethylformamide ( mL). The reaction mixture is heated at 65-70°C for 2 hrs. Removal of solvent gives a crude residue which is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate:toluene, 1:4 ) to give 4-methyl{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]- oxadiazolyl]benzyl}piperidinecarboxylic acid ethyl ester.
Step (d) Cl Cl N O N OH O N O N A solution of sodium hydroxide (0.1 g, 0.0023 mol) and potassium hydroxide (85% assay, 0.13 g, 0.0020 mol) in demineralized water (2 mL) is added to a solution of 4-methyl- 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} piperidinecarboxylic acid ethyl ester (0.3 g, 0.00057 mol) in tetrahydrofuran and ethanol (14 mL, 1:1). The reaction mixture is heated under reflux (80°C) for 2 hrs. It is then concentrated under reduced pressure to give a crude residue which is dissolved in demineralized water (10 mL) and acidified to pH~4-5 with 20% aqueous acetic acid solution. The resultant solid is filtered, dried and washed with acetone (2x10 mL). Solid is dried under vacuum to get 1-{4-[5-(3- chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl}4-methyl piperidinecarboxylic acid.
Example 2: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid, tert-butylamine salt Step (a) Cl Cl OH O N N,N’-Dicyclohexylcarbodiimide (1.07 g, 0.0052 mol) is added to a solution of 3-chloro- 4-isobutylbenzoic acid (0.74 g, 0.0035 mol), N-hydroxyhydroxymethylbenzamidine (0.867g, 0.0052 mol) and N-hydroxybenzotriazole monohydrate (0.798 g, 0.0052 mol) in N,N- dimethylformamide (15 mL). The reaction mixture is heated at 120-125 C for 2 hrs. It is then cooled to 0-5°C, filtered and washed with dichloromethane (2x20 mL). The filtrate is evaporated under reduced pressure and the residue is treated with demineralized water (20 mL). It is extracted with ethyl acetate (2x30 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 15:85) to give {4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-phenyl}methanol.
Step (b) Cl Cl OH Cl O N O N Thionyl chloride (3.1 mL, 0.043 mol) and N,N-dimethylformamide (0.2 mL) are added to a stirred solution of {4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-phenyl} methanol (4.9 g, 0.0143 mol) in dichloromethane (30 mL) at 0°C. The reaction mixture is heated at 40-45°C and is stirred at this temperature for 30 minutes. It is then cooled to 0-5 C temperature, treated with demineralized water (3 mL) and neutralized with caustic lye to adjust the pH to 8-9. Finally it is extracted with dichloromethane (2x20 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives 5-(3- chloroisobutylphenyl)(4-chloromethylphenyl)-[1,2,4]-oxadiazole.
Step (c) Cl Cl Cl N N N O O N O N Potassium carbonate (0.29 g, 0.0021 mol) and 4-methylpiperidinecarboxylic acid ethyl ester (0.36 g, 0.0021 mol) are added to a solution of 5-(3-chloroisobutylphenyl)(4- chloromethylphenyl)-[1,2,4]-oxadiazole (0.5 g, 0.0014 mol) in N,N-dimethylformamide (10 mL). The reaction mixture is heated at 65-70°C for 2 hours. Removal of solvent gives a crude residue which is purified by column chromatography (silica gel 230-400 mesh, toluene:ethyl acetate 4:1) to give 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}methylpiperidinecarboxylic acid ethyl ester.
Step (d) O N NH A solution of sodium hydroxide (0.22 g, 0.0055 mol) and potassium hydroxide (85% assay, 0.3 g, 0.0046 mol) in demineralized water (1 mL) is added to a solution of 1-{4-[5-(3- chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid ethyl ester (0.67 g, 0.0014 mol) in (14 mL) of tetrahydrofuran and ethanol mixture (1:1). The reaction mixture is heated at 80ºC temperature for 4 hrs. It is then concentrated under reduced pressure to give a crude residue which is treated with demineralized water (20 mL) and acidified to pH~4-5 with 20% aqueous acetic acid solution (10 mL). The resultant solid is filtered, dried and washed with demineralized water (1x20 mL) and acetone (2x5 mL) respectively. The resultant solid is treated with a solution of methanol, dichloromethane and t- butylamine (2:7.5:0.5, 20 mL) and concentrated under reduced pressure. The solid mass is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t- butylamine,1:8.9:0.1) to get 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}- 4-methylpiperidinecarboxylic acid t-butyl amine salt.
Example 3: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid Cl Cl O OH O N O N An aqueous solution of 20% acetic acid (1 mL) is added to a slurry of 1-{4-[5-(3- chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid t- butyl amine salt (0.2 g, 0.00035 mol) in demineralized water (10 mL) to adjust the pH of the solution to 4 - 5. The solution is stirred at room temperature for 30 minutes, filtered and washed with demineralized water (2x5 mL) & acetone (1x5 mL). Finally it is dried to get 1-{4- [5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid as free acid.
Example 4: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid, sodium salt Cl Cl N OH N O O N O N Na An aqueous solution of sodium hydroxide (0.006 g, 0.00015 mol) is added to a slurry of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidine carboxylic acid (0.065 g, 0.00014 mol) in tetrahydrofuran (5 mL). The solution is stirred at room temperature for 30 minutes and concentrated under reduced pressure to get sodium salt of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidine carboxylic acid.
Examples 5 & 6 may be prepared in the manner as mentioned for sodium salt (Example 4).
Example 5: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid, arginine salt N OH OH NH N NH Example 6: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid, potassium salt Example 7: 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid N OH A solution of sodium hydroxide (0.13 g, 0.0033 mol) and potassium hydroxide (85% assay, 0.22 g, 0.0033 mol) in demineralized water (5 mL) is added to a solution of 1-{4-[5-(3- chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid ethyl ester (0.43 g, 0.0008 mol) in a mixture of tetrahydrofuran and ethanol (1:1), 10 ML.
The reaction mixture is heated at 80ºC temperature for 3 hrs. It is then concentrated under reduced pressure to give a crude residue which is treated with demineralized water (20 mL) and acidified to pH~4-5 with 20% aqueous acetic acid solution (10 mL). The resultant solid is filtered, dried and washed with demineralized water (1x20 mL) and acetone (2x5 mL) respectively. Finally it is dried under reduced pressure to get 1-{4-[5-(3-chloro cyclopentylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}methylpiperidinecarboxylic acid.
Example 8: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid N OH Example 8 may be prepared in a manner as mentioned above for Example 7.
Example 9: 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butyl amine salt Step (a) Potassium carbonate (0.28 g, 0.002 mol) and 4-methoxymethylpiperidinecarboxylic acid ethyl ester (0.4 g, 0.002 mol) are added to a solution of 5-(3-Chlorocyclopentyl- phenyl)(4-chloromethyl-phenyl)-[1,2,4]oxadiazole (0.5 g, 0.0013 mol) in N,N- dimethylformamide (15 mL). The reaction mixture is heated at 65-70°C for 2 hours. Removal of solvent gives a crude residue which is purified by column chromatography (silica gel 230- 400 mesh, toluene:ethyl acetate 4:1) to give 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]- oxadiazolyl]benzyl}methoxy methyl piperidinecarboxylic acid ethyl ester.
Step (b) N O N OH O N O N Potassium hydroxide powder (85% assay, 0.32 g, 0.0049 mol) and 18-crownether (0.01 g) are added to a solution of 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazol yl]benzyl}methoxymethylpiperidinecarboxylic acid ethyl ester (0.3 g, 0.00056 mol) in dry toluene (15 mL). The reaction mixture is refluxed for 3 hrs. It is then concentrated under reduced pressure and the residue is acidified to pH~ 4-5 with 20% aqueous solution of acetic acid (10 mL). The precipitated solid is filtered, dried and washed with demineralised water (2x10 mL) and acetone (2x5 mL). Solid mass is dissolved in a solution of methanol:dichlromethane:t-butylamine (1:8.9:0.1; 5 mL) and concentrated under reduced pressure to get crude residue which is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(3-chloro cyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidinecarboxylic acid.
Examples 10 to 28 may be prepared in similar manner as that mentioned for Example Example 10: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butyl amine salt Example 11: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} ethylpiperidinecarboxylic acid tert-butyl amine salt N OH Example 12: 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol yl]benzyl}piperidinecarboxylic acid tert-butyl amine salt N OH Example 13: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} propylpiperidinecarboxylic acid tert-butyl amine salt N OH Example 14: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butyl amine salt N OH Example 15: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} hydroxymethylpiperidinecarboxylic acid tert-butyl amine salt N OH Example 16: 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl} methoxymethylpiperidinecarboxylic acid tert-butyl amine salt ON O Example 17: 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butyl amine salt N OH ON 2 Example 18: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} propylpiperidinecarboxylic acid tert-butyl amine salt N OH Example 19: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butyl amine salt N OH Example 20: 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butyl amine salt N OH ON O Example 21: 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol yl]-benzyl}piperidinecarboxylic acid tert-butyl amine salt N OH Example 22: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} hydroxymethylpiperidinecarboxylic acid tert-butyl amine salt ON OH Example 23: 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]- oxadiazolyl]-benzyl} phenylpiperidinecarboxylic acid tert-butyl amine salt N OH NH Ph Example 24: 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}- piperidinecarboxylic acid tert-butyl amine salt ON Ph Example 25: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-fluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 26: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-fluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt Example 27: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (4-methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 28: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl} (2-methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 29: 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butyl amine salt O OH O Cl 2 Potassium hydroxide powder (85% assay, 0.394 g, 0.0060 mol) and N-methyl-N,N- dioctyloctanammonium chloride (0.02 g) are added to a solution of 1-{4-[5-(2- chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethylpiperidinecarboxylic acid ethyl ester (0.38 g, 0.00069 mol) in N,N'-dimethyl formamide (5 mL). The reaction mixture is stirred at 80ºC temperature for 2 hrs. It is then cooled to room temperature and acidified with 20% aqueous acetic acid solution to pH~5-6. The precipitated solid is filtered, dried and washed with (2x5 mL) acetone. The solid mass is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methoxymethyl- piperidinecarboxylic acid.
Example 30: 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} ethylpiperidinecarboxylic acid tert-butyl amine salt Step (a) N,N’-Dicyclohexylcarbodiimide (4 g, 0.019 mol) is added to a solution of 2- chlorobiphenylcarboxylic acid (3 g, 0.013 mol), N-hydroxyhydroxymethyl benzamidine (2.9 g, 0.017 mol) and N-hydroxybenzotriazole monohydrate (2.9 g, 0.019 mol) in N,N- dimethylformamide (40 mL). The reaction mixture is heated at 120-125 C for 3 hrs. It is then cooled to 0-5°C, filtered and washed with dichloromethane (2x15 mL). The filtrate is evaporated under reduced pressure and the residue is treated with demineralized water (20 mL). It is extracted with ethyl acetate (2x20 mL) and the combined extract is dried over sodium sulfate. Removal of solvent under reduced pressure gives a crude residue which is purified by column chromatography (silica gel 230-400, ethyl acetate:toluene, 1:9) to give {4- [5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-phenyl}-methanol.
Step (b) Pyridiniumchlorochromate (3.6 g, 0.017 mol) is added to a solution of {4-[5-(2- chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-phenyl}-methanol (4.0 g, 0.011 mol) in dichloromethane (40 mL). The reaction mixture is stirred at room temperature for 30 minutes, filtered and washed with dichloromethane (40 mL). Filtrate is concentrated under reduced pressure to give crude which is purified by column chromatography (230;400 mesh: 9.5:0.5 toluene : ethyl acetate) to yield 4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzaldehyde.
Step (c) A solution of 4-ethylpiperidinecarboxylic acid (0.45 g, 0.00283 mol) in demineralized water (3 mL) is added to a solution of 4-[5-(2-chloroisobutylphenyl)-[1,2,4]- oxadiazoleyl]benzaldehyde (0.685 gm, 0.0019 mol) in methanol and dichloromethane (1:3, mL). Acetic acid (1.1 mL) is added to the reaction mixture. The reaction mixture is stirred at room temperature for 30 minutes. A solution of sodium cyanoborohydried (0.238 gm, 0.0038 mol) in methanol (2 mL) is added to the reaction mixture and stirred for 1.5 hrs at room temperature. Solvent is removed from the reaction mixture under reduced pressure to get a crude solid which is treated with demineralized water (10 mL) and filtered. Solid mass is dissolved in a solution of methanol:dichlromethane:t-butylamine (1:8.9:0.1; 15 mL) and concentrated under reduced pressure to get crude residue which is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine carboxylic acid.
Example 31 may be prepared in a manner as mentioned above for Example 2.
Example 31: 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt Example 32: 1-{4-[5-(3-Chloroisobutylphenyl-[1,2,4]-oxadiazolyl]benzyl}(4- methoxybutyl)piperidinecarboxylic acid tert-butyl amine salt N OH ON O An aqueous solution (0.5 mL) of potassium hydroxide (0.39 g, 0.0059 mol, assay 85%) is added to a solution of 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazol yl]benzyl}(4-methoxybutyl)piperidinecarboxylic acid ethyl ester (0.48 g, 0.0008 mol) in a mixture of tetrahydrofuran (5 mL) and ethanol (5 mL). The reaction mixture is heated at 75- 80ºC for 20 hrs, cooled to room temperature and then concentrated under reduced pressure.
The residue is treated with demineralized water (10 mL) and acidified to pH~5-5.5 using 20% aqueous acetic acid (15 mL). The precipitated solid is filtered, washed with demineralized water (10 mL) and acetone (10 mL). The Solid mass is dissolved in a solution of methanol:dichlromethane:t-butylamine (1:8.9:0.1; 5 mL) and concentrated under reduced pressure to get crude residue which is purified by column chromatography (silica gel 230-400 mesh, methanol:dichloromethane:t-butylamine,1:8.9:0.1) to give 1-{4-[5-(3-chloro isobutylphenyl-[1,2,4]-oxadiazolyl]benzyl}(4-methoxybutyl)piperidinecarboxylic acid.
Example 33: 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid potassium salt N OH ON O 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid ethyl ester (6g, 0.01052 mol) is added in to a solvent mixture containing THF (120ml, 20vol) and Rectified Spirit (120ml, 20vol). Stirred to get a clear solution at RT. Potassium Hydroxide (4.17g, 0.06315mol) is charged in to the above reaction flask at RT. The reaction mixture is heated at 70-80ºC temperature for 10- 12hrs. It is then concentrated under reduced pressure to give a crude residue which is codistilled with acetone (12 ml, 2vol) and suspended in aq. Acetone [5% water, 90ml, 15vol].
Stirred the product slurry at 30-40 C for 30mins. Cooled to 0-5 C and stirred for 1-2hrs. The resultant solid is filtered, dried and washed with aq. Acetone [5% water, 48ml, 8vol]. Suck dried the product under nitrogen for 30-60mins and further dried under vacuum at 450C to yield 7g [M/C: 12%] of Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazol- 3-yl]-benzyl}(2-methoxy-ethoxymethyl)-piperidinecarboxylic acid.
The above product is leached with Ethyl acetate and dried under vacuum to yield 6.8g of Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)-piperidinecarboxylic acid.
The potassium salt [6.15gm] is crystallized from Methanol to yield 4.5g of pure Potassium salt of 1-{4-[5-(3-chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2- methoxy-ethoxymethyl)-piperidinecarboxylic acid.
Examples 34-35 may be prepared in a similar manner as that mentioned for Example Example 34: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- phenoxy-ethyl)-piperidinecarboxylic acid tert-butyl amine salt Example 35:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6- difluoro-benzyl)-piperidinecarboxylic acid tert-butyl amine salt Examples 36-38 may be prepared in similar manner as that mentioned for Example Example 36:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} isobutyl-piperidinecarboxylic acid tert-butyl amine salt Example 37:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} isopropyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 38:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3- trifluoro methyl-benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Examples 39 - 41 may be prepared in similar manner as that mentioned for Example Example 39:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furan- 2-ylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 40:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 41:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2- methoxy-phenoxy)-ethyl]-piperidinecarboxylic acid tert-butyl amine salt Examples 42-43 may be prepared in similar manner as that mentioned for Example 9.
Example 42:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 43:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt Examples 44-47 may be prepared in similar manner as that mentioned for Example 2.
Example 44:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 45:1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methyl-piperidinecarboxylic acid tert-butyl amine salt Example 46:1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt N OH Example 47:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxy-ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt ON O Examples 48-58 may be prepared in similar manner as that mentioned for Example 9 Example 48:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} ethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 49:4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]- benzyl}-piperidinecarboxylic acid tert-butyl amine salt Example 50:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 51:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4- methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 52:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro- benzyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 53:1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4- methoxy-benzyl)-piperidinecarboxylic acid tert-butyl amine salt Example 54:1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl} ethyl-piperidinecarboxylic acid tert-butyl amine salt Example 55:4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}- piperidinecarboxylic acid tert-butyl amine salt Example 56:1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} pyridinylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Example 57:1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methoxymethyl-piperidinecarboxylic acid tert-butyl amine salt N OH ON O Example 58:1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt Example 59 may be prepared in similar manner as that mentioned for Example 2.
Example 59:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- ethoxy-ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Examples 60 may be prepared in similar manner as that mentioned for Example 9.
Example 60:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} isopropoxy methyl-piperidinecarboxylic acid tert-butyl amine salt Examples 61 may be prepared in similar manner as that mentioned for Example 32.
Example 61:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopentyloxymethyl-piperidinecarboxylic acid tert-butyl amine salt ON O Examples 62 may be prepared in similar manner as that mentioned for Example 9.
Example 62:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} thiophenylmethyl-piperidinecarboxylic acid tert-butyl amine salt Examples 63 may be prepared in similar manner as that mentioned for Example 30.
Example 63:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopropylmethyl-piperidinecarboxylic acid tert-butyl amine salt N OH Examples 64-66 may be prepared in similar manner as that mentioned for Example 9.
Example 64:1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- morpholinyl-ethyl)-piperidinecarboxylic acid N OH Example 65: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3- piperidinyl-propyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Example 66: 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3- pyrrolidinyl-propyl)-piperidinecarboxylic acid tert-butyl amine salt N OH Ex. MS Structure NMR data No. (ES+) as free form PMR : (CDCl +CD OD+TFA; 400.13 MHz ; ppm) 1.25-1.60 (s merged in m, 9H); 1.75-2.02 (br 494.24 m, 6H); 2.40 (d, J=14.64 Hz, 2H); 2.83-3.07 (br t, 2H); 3.07-3.19 (br t, 1H); 3.54-3.68 (br d, 2H); 4.33 (s, 2H);7.42-7.62 (m, 3H); 8.05 (d, J=7.78 Hz, 1H); 8.17-8.27 (br d, 3H) One exchangeable proton as free form PMR : (CDCl +CD OD+TFA; 400.13 MHz ; ppm) 0.97 (d, J=5.99 Hz, 6H); 1.30 (s, 3H); 1.74- O 1.88 (br t, 2H); 2.00-2.12 (br m, 1H); 2.35 (d, 468.23 J=14.49 Hz, 2H); 2.69-2.77 (br d, 2H); 2.89- N OH 3.01 (br t, 2H); 3.48-3.59 (br d, 2H); 4.28 (s, 2H); 7.48-7.43 (br d, 1H); 7.54-7.62 (br d, 2H); 7.99-8.05 (br d, 1H); 8.18-8.27 (br d, One exchangeable proton As free form PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ; ppm) 1.29 (s, 3H); 1.57-1.67 (br m, 2H); 1.72-1.92 7 (br m, 6H); 2.12-2.22 (br m, 2H); 2.31 (d, 480.23 N OH J=14.60 Hz, 2H); 2.88 (t, J=12.50 Hz, 2H); O N 3.48-3.58 (br m, 3H); 4.36 (s, 2H); 7.50 (d, J=7.15 Hz, 1H); 7.55 (d, J=7.95 Hz, 2H); 8.04 (d, J=8.00 Hz, 1H); 8.18-8.26 (br m, 3H) One exchangeable proton As free form PMR:CDCl +CD OD+TFA; 500.13 MHz ; d ppm) 1.29 (s, 3H); 1.81-1.90 (br t, 2H); 2.31 (d, J=14.40 Hz, 2H); 2.86-2.95 (br t, 2H); 3.46- 8 488.24 N OH 3.53 (br d, 2H); 4.26 (s, 2H); 7.43-7.53 (br m, 5H); 7.55-7.64 (m, 3H); 8.16 (dd, J1=7.90 Hz, J =1.00 Hz, 1H); 8.25 (d, J=8.05 Hz, 2H); 8.35 (s, J=0.90 Hz, 1H); One exchangeable proton as t-butyl amine salt PMR : (CDCl3+D2O; 500.13 MHz ; d ppm) 1.28 (s, 9H); 1.55-1.65 (br m, 4H); 1.71-1.80 (br m, 2H); 1.80-1.89 (br m, 2H); 2.10-2.18 (br m, 4H); 2.38-2.46 (br t, 2H); 2.71-2.77 (br 9 510.21 d, 2H); 3.29 (s, 3H); 3.41 (s, 2H); 3.46-3.56 (m, 1H); 3.63 (s, 2H); 7.44-7.51 (m, 3H); 8.01 O N O (d, J=8.30 Hz, 1H); 8.08 (d, J=8.05 Hz, 2H); 8.18 (d, J=0.90 Hz, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 1.29-1.31 (s merged in m, 10H); 1.37-1.54 (m, 4H); 1.54-1.63 (m, 2H); 1.78-1.85 (br d, 1H); 1.91 (t, J=13.20 Hz, 4H); 2.13 (d, J=13.45 Hz, 2H); 2.37 (t, J=10.20 Hz, 2H); 524.21 N OH 2.74-2.82 (br d, 2H); 3.06-3.14 (m, 1H); 3.30 (s, 3H); 3.40 (s, 2H); 3.64 (s, 2H); 7.46-7.52 O N O (m, 3H); 8.05 (dd, J1=8.20 Hz, J2=1.50 Hz, 1H); 8.10 (d, J=8.15 Hz, 2H); 8.19 (d, J=1.35 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm) 0.85 (t, J=7.45 Hz, 3H); 0.97 (d, J=6.60 Hz, NH 6H); 1.26 (s, 9H); 1.42-1.57 (m, 4H); 2.01- 2.08 (m, 1H); 2.12 (d, J=13.40 Hz, 2H); 2.27 481.94 (t, J=11.00 Hz, 2H); 2.71 (d, J=7.20 Hz, 2H); N OH 2.75—2.82 (br d, 2H); 3.60 (s, 2H); 7.38 (d, J=8.00 Hz, 1H); 7.48 (d, J=8.05 Hz, 2H); 8.02 (dd, J =7.90 Hz, J =1.40 Hz, 1H); 8.10 (d, J=8.05 Hz, 2H); 8.20 (d, J=1.10 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.55 Hz, 6H); 1.26 (s, 9H); 1.48- 1.56 (br t, 2H); 2.00-2.13 (m, 3H); 2.24-2.34 (m, 4H); 2.70 (d, J=7.20 Hz, 2H); 2.72-2.79 493.94 (br d, 2H); 3.60 (s, 2H); 4.98-5.06 (m, 2H); N OH .73-5.83 (m, 1H); 7.38 (d, J=7.95 Hz, 1H); 7.48 (d, J=8.10 Hz, 2H); 8.01 (dd, J =7.90 Hz, J =1.15 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H); 8.20 (d, J=1.25 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.79 (t, J=7.10 Hz, 3H); 0.89 (d, J=6.55 Hz, NH 6H); 1.15 (s, 9H); 1.16-1.24 (br m, 2H); 1.33- 1.45 (br m, 4H); 1.92-2.00 (m, 1H); 2.00-2.07 495.95 (br d, 2H); 2.12 (br t, 2H); 2.63 (d, J=7.20 Hz, 2H); 2.64-2.71 (br d, 2H); 3.50 (s, 2H); 7.30 (d, J=7.95 Hz, 1H); 7.39 (d, J=7.95 Hz, 2H); 7.94 (d, J=7.95 Hz, 1H); 8.02 (d, J=8.00 Hz, 2H); 8.12 (s, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl ; 400.13 MHz ; d ppm) 0.96 (d, J=6.61 Hz, 6H); 1.26 (s, 9H); 1.53- N OH 542.04 1.63 (br t, 2H); 1.98-2.08 (m, 1H); 2.13-2.22 (br d, 2H); 2.35-2.44 (br t, 2H); 2.69 (d, O N O J=7.19 Hz, 2H); 2.73-2.80 (br d, 2H); 3.36 (s, 3H); 3.49 (s, 2H); 3.42-3.60 (br d, 4H); 3.62 Ex. MS Structure NMR data No. (ES+) (s, 2H); 7.35 (7.97 Hz, 1H); 7.48 (d, J=8.04 Hz, 2H); 8.00 (dd, J =7.99 Hz, J =1.17 Hz, 1H); 8.09 (d, J=8.08 Hz, 2H); 8.20 (d, J=1.03 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ; ppm) 0.97 (d, J=6.60 Hz, 6H); 1.39 (s, 9H); 1.84- 1.95 (br t, 2H); 2.00-2.11 (m, 1H); 2.31 (d, J=14.60 Hz, 2H); 2.71 (d, J=7.20 Hz, 2H); N OH 483.96 3.02 (d, J=12.60 Hz, 2H); 3.54 (d, J=11.80 Hz, 2H); 3.66 (s, 2H); 4.27 (s, 2H); 7.39 (d, J=7.95 Hz, 1H); 7.58 (d, J=8.10 Hz, 2H); =7.95 Hz, J =1.55 Hz, 1H); 8.19- 8.01 (dd, J1 2 8.25 (m, 3H) Four exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.62 Hz, 6H); 1.29 (s, 9H); 1.53- 1.63 (br m, 2H); 1.98-2.09 (m, 1H); 2.09-2.17 (br d, 2H); 2.37 (t, J=10..67 Hz, 2H); 2.70 (d, N OH 16 498.19 J=7.21 Hz, 2H); 2.74-2.82 (br d, 2H); 3.30 (s, 3H); 3.39 (s, 2H); 3.63 (s, 2H); 7.38 (d, ON O J=7.99 Hz, 1H); 7.49 (d, J=8.10 Hz, 2H); 8.01 (dd, J1=7.91 Hz, J2=1.36 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H); 8.20 (d, J=1.28 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm) 1.28 (s, 9H); 1.50-1.58 (br t, 2H); 2.11 (d, O J=13.40 Hz, 2H); 2.26 (d, J=7.25 Hz, 2H); 2.28-2.36 (br t, 2H); 2.76-2.83 (br d, 2H); N OH 17 513.93 3.63 (s, 2H); 4.99-5.07 (m, 2H); 5.73-5.82 (m, 1H); 7.43-7.52 (m, 7H); 7.55 (d, J=8.05 Hz, 1H); 8.12 (d, J=8.15 Hz, 2H); 8.16 (dd, J =8.00 Hz, J = 1.60 Hz, 1H); 8.34 (d, J=1.50 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm) 0.88 (t, J=7.15 Hz, 3H); 1.25 (s, 9H); 1.27- 1.34 (m, 2H); 1.43-1.55 (m, 4H); 2.13 (d, J=13.40 Hz, 2H); 2.26 (t, J=10.90 Hz, 2H); 18 N OH 515.95 Cl 2.74-2.82 (br d, 2H); 3.60 (s, 2H); 7.43-7.52 (m, 7H); 7.55 (d, J=7.95 Hz, 1H); 8.12 (d, J=8.00 Hz, 2H); 8.16 (dd, J =8.00 Hz, J =1.45 Hz, 1H); 8.34 (d, J=1.25 Hz, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl ; 400.13 MHz ; d ppm) 1.31 (s, 9H); 1.52-1.62 (br t, 2H); 2.13-2.22 (br d, 2H); 2.34-2.45 (br t, 2H); 2.73-2.82 (br N OH 19 561.99 d, 2H); 3.37 (s, 3H); 3.48 (s, 2H); 3.52-3.59 ON O (br s, 4H); 3.62 (s, 2H); 7.41-7.56 (m, 8H); 8.09-8.17 (m, 3H); 8.34 (s, 1H) Three exchangeable protons as t-butyl amine salt PMR : ( CDCl3; 500.13 MHz ; d ppm) 1.21 (s, 9H); 1.60-1.68 (br t, 2H); 2.17 (d, J=13.45 Hz, 2H); 2.37-2.47 (br t, 2H); 2.71- N 2.78 (br d, 2H); 3.49 (s, 2H); 3.62 (s, 2H); 594.00 N OH 4.48 (s, 2H); 7.28-7.32 (m, 5H); 7.43-7.50 (m, 7H); 7.52 (d, J=8.00 Hz, 1H); 8.09 (d, J=8.20 Hz, 2H); 8.13 (dd, J =8.00 Hz, J =1.70 Hz, 1H); 8.32 (d, J=1.50 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR :(CDCl +CD OD+D O; 500.13 MHz ; 3 3 2 ppm) 0.96 (d, J=6.60 Hz, 6H); 1.21 (s, 9H); 1.57- O 1.66 (br t, 2H); 1.98-2.07 (m, 1H); 2.15 (d, J=13.15 Hz, 2H); 2.38-2.48 (br t, 2H); 2.66- 21 574.03 Cl 2.75 (d merged in m, 4H); 3.49 (s, 2H); 3.61 ON O (s, 2H); 4.47 (s, 2H); 7.23-7.31 (m, 5H); 7.35 (d, J=8.10 Hz, 1H); 7.46 (d, J=8.10 Hz, 2H); 7.99 (dd, J1=7.95 Hz, J2=1.15 Hz, 1H); 8.07 (d, J=8.15 Hz, 2H); 8.19 (d, J=1.45 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : CDCl3+CD3OD+TFA; 500.13 MHz ; d ppm) 1.38 (s, 9H); 1.87-1.97 (br t, 2H); 2.30 (d, J=14.55 Hz, 2H); 2.99 (t, J=12.50 Hz, 2H); 22 N OH 503.91 3.53 (d, J=12.05 Hz, 2H); 3.65 (s, 2H); 4.26 (s, 2H); 7.43-7.50 (m, 5H); 7.56 (d, J=8.00 ON OH Hz, 1H); 7.60 (d, J=8.10 Hz, 2H); 8.16 (dd, J =8.00 Hz, J =1.35 Hz, 1H); 8.25 (d, J=8.15 Hz, 2H); 8.35 (d, J=1.50 Hz, 1H) Four exchangeable protons as t-butyl amine salt PMR : CDCl +CD OD+TFA; 500.13 MHz ; d ppm) 0.98 (d, J=6.65 Hz, 6H); 1.37 (s, 9H); 2.01- N 2.11 (m, 1H); 2.18-2.27 (br dt, 2H); 2.72 (d, 23 530.19 N J=7.20 Hz, 2H); 2.81 (d, J=13.90 Hz, 2H); 3.05 (t, J=12.90 Hz, 2H); 3.65-3.72 (br d, 2H); 4.32 (s, 2H); 7.33-7.39 (m, 5H); 7.40 (d, J=8.05 Hz, 1H); 7.60 (d, J=8.20 Hz, 2H); 8.03 (dd, J1=7.90 Hz, J2=1.60 Hz, 1H); 8.20- 8.27 (m, 3H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : CDCl +CD OD+TFA; 500.13 MHz ; d ppm) 0.86 (d, J=6.50 Hz, 6H); 1.31 (s, 9H); 1.82- 1.98 (m, 3H); 2.21-2.27 (br d, 2H); 2.61 (d, J=7.15 Hz, 2H); 2.71-2.84 (s merged in m, 24 544.22 N OH 4H); 3.50-3.57 (br d, 2H); 4.17 (s, 2H); 6.92- 6.98 (br d, 2H); 7.13-7.17 (br s, 3H); 7.29 (d, J=7.95 Hz, 1H); 7.42 (d, J=7.85 Hz, 2H); 7.90 (d, J=7.80 Hz, 1H); 8.10 (d, J=3.55 Hz, Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ; d ppm) 0.98 (d, J=6.65 Hz, 6H); 1.40 (s, 9H); 1.83- N 1.93 (br dt, 2H); 2.02-2.10 (m, 1H); 2.30-2.35 N OH (br d, 2H); 2.74 (d, J=7.25 Hz, 2H); 2.88 (s, 562.17 2 2H); 2.96 (t, J=13.05 Hz, 2H); 3.52-3.58 (br d, 2H); 4.28 (s, 2H); 6.96 (t, J=8.65 Hz, 2H); 7.04-7.09 (m, 2H); 7.42 (d, J=7.95 Hz, 1H); 7.57 (d, J=8.20 Hz, 2H); 8.03 (dd, J =7.85 Hz, J2=1.75 Hz, 1H); 8.20-8.24 (m, 3H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.26 (s, 9H); 1.53- 1.61 (br t, 2H); 2.01-2.13 (m, 3H); 2.22-2.28 (br t, 2H); 2.71 (d, J=7.25 Hz, 2H); 2.77-2.84 N OH 26 562.19 (br d, 2H); 2.88 (s, 2H); 3.57 (s, 2H); 6.95- 7.04 (m, 2H); 7.13-7.22 (m, 2H); 7.38 (d, J=7.95 Hz, 1H); 7.46 (d, J=8.15 Hz, 2H); 8.02 (dd, J1=7.90 Hz, J2=1.40 Hz, 1H); 8.08 (d, J=8.15 Hz, 2H); 8.20 (d, J=1.40 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3+CD3OD+TFA; 500.13 MHz ; d ppm) 0.98 (d, J=6.45 Hz, 6H); 1.37 (s, 9H); 1.82- N 1.91 (m, 2H); 2.03-2.10 (m, 1H); 2.27-2.34 N OH (br d, 2H); 2.73 (d, J=7.10 Hz, 2H); 2.84 (s, 2 574.23 2H); 2.88-2.97 (br t, 2H); 3.47-3.53 (br d, 2H); 3.78 (s, 3H); 4,25 (s, 2H); 6.81 (d, J=8.35 Hz, 2H); 7.02 (d, J=8.25 Hz, 2H); 7.40-7.44 (br d, 1H); 7.57 (d, J=8.05 Hz, 2H); 8.03 (d, J=7.90 Hz, 1H); 8.20-8.25 (br d, 3H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.55 Hz, 6H); 1.26 (s, 9H); 1,53- O 1.61 (br t, 2H); 2.01-2.10 (m, 3H); 2.20-2.26 (br t, 2H); 2.70 (d, J=7.20 Hz, 2H); 2.78-2.82 N OH 28 574.23 (br d, 2H); 2.90 (s, 2H); 3.56 (s, 2H); 3.76 (s, 3H); 6.80-6.85 (m, 2H); 7.10-7.18 (m, 2H); 7.37 (d, J=8.00 Hz, 1H); 7.45 (d, J=8.05 Hz, 2H); 8.01 (d, J=7.95 Hz, 1H); 8.08 (d, J=8.00 Hz, 2H); 8.20 (s, 1H) Three exchangeable protons as t-butyl amine salt O N PMR : (CDCl +CD OD; 400.13 MHz ; d ppm) CO H 1.30 (s, 9H); 1.53-1.64 (br m, 2H); 2.10-2.18 CH OCH (br d, 2H); 2.33-2.42 (br t, 2H); 2.74-2.82 (br 29 518.17 d, 2H); 3.31 (s, 3H); 3.37-3.43 (br s, 2H); Cl NH 3.64 (s, 2H); 7.42-7.53 (m, 7H); 7.53 (d, J=10.31 Hz, 1H); 8.11-8.18 (m, 3H); 8.34 (d, J=1.17 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD+TFA; 400.13 MHz ; d ppm) CO H 0.88 (t, J=7.34 Hz, 3H); 1.40 (s, 9H); 1.60- N 1.70 (m, 2H); 1.73-1.85 (br t, 2H); 2.37 (d, N 502.19 J=14.65 Hz, 2H); 2.93 (t, J=12.51 Hz, 2H); 3.57 (d, J=12.32 Hz, 2H); 4.29 (s, 2H); 7.43- 7.54 (br m, 4H); 7.56-7.62 (m, 3H); 8.23-8.28 (br d, 2H); 8.34-8.37 (br s, 1H) Two protons are merged between 8.1-8.2, Three exchangeable protons as t-butyl amine salt NH PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.93 (d, J=6.50 Hz, 6H); 1.16 (s, 3H); 1.28 (s, 9H); 1.46-1.55 (br m, 2H); 1.89-1.99 (m, 434.18 1H); 2.09-2.15 (br d, 2H); 2.31-2.39 (br t, N OH 2H); 2.58 (d, J=7.25 Hz, 2H); 2.70-2.78 (br d, 2H); 3.64 (s, 2H); 7.34 (d, J=7.15 Hz, 2H); 7.48 (d, J=8.15 Hz, 2H); 8.09-8.14 (m, 4H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.56 Hz, 6H); 1.26 (s, 9H); 1.29- 1.36 (br m, 2H); 1.41-1.58 (m, 6H); 2.00-2.09 (m, 1H); 2.11-2.18 (br d, 2H); 2.21-2.29 (br t, 32 NH 540.23 2H); 2.71 (d, J=7.19 Hz, 2H); 2.74-2.81 (br d, 2H); 3.31 (s, 3H); 3.36-3.40 (br m, 2H); 3.59 (s, 2H); 7.39 (d, J=8.02 Hz, 1H); 7.47 (d, N OH O J=8.04 Hz, 2H); 8.02 (d, J=6.90 Hz, 1H); 8.10 (d, J=8.04 Hz, 2H); 8.21 (s, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) As potassium salt : PMR : (CDCl3 + CD3OD; 500.13 MHz ; d ppm) 0.96 (d, J=6.60 Hz, 6H); 1.39-1.46 (br t, 2H); 2.00-2.09 (m, 1H); 2.10-2.16 (br d, 2H); N OH 542.04 2.22-2.30 (br t, 2H); 2.65-2.72 (d merged in m, 4H); 3.35 (s, 3H); 3.43 (s, 2H); 3.50-3.56 ON O (m, 6H); 7.37 (d, J=7.95 Hz, 1H); 7.46 (d, J=8.05 Hz, 2H); 8.01 (dd, J1=7.90 Hz, J2=1.45 Hz, 1H); 8.09 (d, J=8.10 Hz, 2H); 8.20 (d, J=1.40 Hz, 1H) as t-butyl amine salt PMR : (CDCl3 +CD3OD+TFA; 400.13 MHz ; d ppm) 0.96 (d, J=6.53 Hz, 6H); 1.41 (s, 9H); 1.86-1.98 (br t, 2H); 1.98-2.10 (m, 1H); 2.13- 2.20 (br t, 2H); 2.50-2.58 (br d, 2H); 2.71 (d, N OH J=7.16 Hz, 2H); 3.06 (t, J=13.04 Hz, 2H); 574.21 3.60-3.67 (br d, 2H); 4.02-4.09 (br t, 2H); 4.33 (s, 2H); 6.78 (d, J=8.13 Hz, 2H); 6.95 (t, J=7.27 Hz, 1H); 7.21-7.27 (br t, 2H); 7.41 (d, J=8.01 Hz, 1H); 7.56 (d, J=7.84 Hz, 2H); 8.00 (d, J=7.87 Hz, 1H); 8.16-8.22 (m, 3H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.55 Hz, 6H); 1.28 (s, 9H); 1.49- 1.57 (br t, 2H); 2.00-2.07 (m, 1H); 2.12-2.22 (m, 4H); 2.70 (d, J=7.15 Hz, 2H); 2.80-2.85 580.18 N F (br d, 2H); 2.90 (s, 2H); 3.55 (s, 2H); 6.83 (t, J=7.40 Hz, 2H); 7.11-7.19 (m, 1H); 7.38 (d, J=8.00 Hz, 1H); 7.44 (d, J=8.00 Hz, 2H); 8.01 (dd, J =7.90 Hz, J2=1.40 Hz, 1H); 8.07 (d, J=8.00 Hz, 2H); 8.20 (s, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.89 (d, J=6.65 Hz, 6H); 0.97 (d, J=6.60 Hz, 6H); 1.30 (s, 9H); 1.46 (d, J=5.85 Hz, 2H); 1.48-1.56 (m, 2H); 1.68-1.77 (m, 1H); 2.00- 2.09 (m, 1H); 2.12-2.09 (br d, 2H); 2.27-2.35 510.28 (br t, 2H); 2.71 (d, J=7.20 Hz, 2H); 2.75-2.81 (br d, 2H); 3.61 (s, 2H); 7.39 (d, J=8.00 Hz, 1H); 7.49 (d, J=8.15 Hz, 2H); 8.02 (dd, J =7.95 Hz, J =1.60 Hz, 1H); 8.11 (d, J=8.10 Hz, 2H); 8.21 (d, J=1.45 Hz, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ; d ppm) 0.94 (d, J=6.80 Hz, 6H); 0.97 (d, J=6.60 Hz, 6H); 1.43 (s, 9H); 1.83-1.92 (m, 1H); 1.95-2.10 (m, 3H); 2.33 (d, J=14.25 Hz, 496.28 2H); 2.72 (d, J=7.20 Hz, 2H); 2.83-2.94 (br t, N OH 2H); 3.57-3.64 (br d, 2H); 4.29 (s, 2H); 7.40 (d, J=8.00 Hz, 1H); 7.62-7.66 (br d, 2H); 8.01 (dd, J1=7.95 Hz, J2=1.55 Hz, 1H); 8.20-8.24 (br m, 3H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD+TFA; 500.13 MHz ; d ppm) 0.98 (d, J=6.60 Hz, 6H); 1.42 (s, 9H); 1.96-2.10 (m, 3H); 2.31 (d, J=14.50 Hz, 2H); N OH 2.71 (d, J=7.20 Hz, 2H); 2.85 (t, J=12.25 Hz, 612.20 2H); 2.98 (s, 2H); 3.59-3.65 (br d, 2H); 4.26 (s, 2H); 7.26-7.33 (m, 1H); 7.35-7.37 (br s, 1H); 7.38-7.44 (m, 2H); 7.51-7.56 (br d, 3H); 8.02 (dd, J =7.90 Hz, J =1.25 Hz, 1H); 8.20- 8.25 (br d, 3H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.26 (s, 9H); 1.54- 1.62 (br t, 2H); 2.00-2.08 (m, 1H); 2.08-2.14 (br d, 2H); 2.27-2.36 (br t, 2H); 2.71 (d, J=7.25 Hz, 2H); 2.73-2.79 (br d, 2H); 2.87 (s, 534.14 39 N 2H); 3.38 (s, 2H); 6.04 (d, J=3.05 Hz, 1H); 6.23-6.27 (m, 1H); 7.27 (d, J=0.95 Hz, 1H); 7.38 (d, J=7.95 Hz, 1H); 7.47 (d, J=8.10 Hz, 2H); 8.02 (dd, J =7.95 Hz, J =1.55 Hz, 1H); 8.09 (d, J=8.15 Hz, 2H), 8.21 (d, J=1.30 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.50 Hz, 6H); 1.27 (s, 9H); 1.54- 1.62 (br t, 2H); 2.00-2.08 (m, 1H); 2.08-2.14 (br d, 2H); 2.29-2.38 (br t, 2H); 2.70 (d, J=7.25 Hz, 2H); 2.75-2.83 (br d, 2H); 3.00 (s, 545.13 2H); 3.61 (s, 2H); 7.14-7.19 (m, 1H); 7.23 (d, N OH J=7.80 Hz, 1H); 7.38 (d, J=7.95 Hz, 1H); 7.46 (d, J=8.10 Hz, 2H); 7.62 (dt, J1=7.75 Hs, J2=1.45 Hz, 1H); 8.01 (dd, J1=7.85 Hz, J2=1.30 Hz, 1H); 8.09 (d, J=8.15 Hz, 2H), 8.20-8.22 (br s, 1H); 8.39-8.42 (br d, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.28 (s, 9H); 1.56- 1.66 (br m, 2H); 2.00-2.10 (m, 3H); 2.16-2.23 (br d, 2H); 2.29-2.37 (br t, 2H); 2.71 (d, N OH J=7.25 Hz, 2H); 2.74-2.82 (br d, 2H); 3.61 (s, 604.12 41 O 2H); 3.83 (s, 3H); 4.08 (t, J=7.65 Hz, 2H); 6.84-6.92 (m, 4H); 7.38 (d, J=7.95 Hz, 1H); 7.48 (d, J=8.05 Hz, 2H); 8.01 (dd, J1=7.90 Hz, J2=1.10 Hz, 1H); 8.10 (d, J=8.05 Hz, 2H); 8.20 (d, J=1.00 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (Pyridine-d ; 500.13 MHz ; d ppm) 0.90 (d, J=6.60 Hz, 6H); 1.23 (s, 9H); 1.72- 1.81 (m, 2H); 1.92-2.02 (m, 1H); 2.39-2.51 (br m, 4H); 2.62 (d, J=7.25 Hz, 2H); 2.81- 2.89 (br m, 2H); 3.05 (s, 2H); 3.53 (s, 2H); 545.16 N OH 7.17-7.21 (m, 1H); 7.36 (d, J=7.95 Hz, 1H); 7.64 (d, J=8.05 Hz, 2H); 7.67-7.70 (br d, 1H); N 8.08 (dd, J1=7.95 Hz, J2=1.65 Hz, 1H); 8.32 (d, J=1.60 Hz, 1H); 8.40 (d, J=8.05 Hz, 2H); 8.61-8.64 (br m, 1H); 8.82-8.85 (br d, 1H) Three exchangeable protons as t-butyl amine salt PMR : (Pyridine-d ; 500.13 MHz ; d ppm) 0.90 (d, J=6.65 Hz, 6H); 1.21 (s, 9H); 1.72- 1.81 (m, 2H); 1.92-2.02 (m, 1H); 2.39-2.47 (br d, 2H); 2.49 (t, J=11.10 Hz, 2H); 2.62 (d, OH J=7.25 Hz, 2H); 2.82-2.89 (br m, 2H); 3.04 545.14 (s, 2H); 3.54 (s, 2H); 7.32 (d, J=5.80 Hz, 2H); 7.37 (d, J=8.00 Hz, 1H); 7.65 (d, J=8.05 Hz, 2H); 8.08 (dd, J1=7.85 Hz, J2=1.50 Hz, 1H); 8.32 (d, J=1.45 Hz, 1H); 8.40 (d, J=8.00 Hz, 2H); 8.67 (d, J=5.70 Hz, 2H); Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) NH 3 3 1.18 (s, 3H); 1.26 (s, 9H); 1.45 (d, J=6.05 Hz, 6H); 1.47-1.53 (br m, 2H); 2.09-2.16 (br 470.11 d, 2H); 2.27-2.36 (br t, 2H); 2.68-2.76 (br d, 44 N 2H); 3.60 (s, 2H); 4.74 (quintet, J=6.10 Hz, 1H); 7.09 (d, J=8.80 Hz, 1H); 7.47 (d, J=8.10 Hz, 2H); 8.06-8.12 (m, 3H); 8.23 (d, J=2.00 Hz, 1H); Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 2 3 3 1.16 (s, 3H); 1.28 (s, 9H); 1.46-1.54 (m, 2H); 1.54 (s, 9H); 2.08-2.16 (br d, 2H); 2.30-2.38 468.11 (br t, 2H); 2.70-2.77 (br s, 2H); 3.63 (s, 2H); 45 N OH 7.49 (d, J=8.15 Hz, 2H); 7.63 (d, J=8.35 Hz, 1H); 8.02 (dd, J =8.30 Hz, J =1.75 Hz, 1H); 8.11 (d, J=8.05 Hz, 2H); 8.19 (d, J=1.80 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm) 1.02 (t, J=7.26 Hz, 3H); 1.17 (s, 3H); 1.27 (s, 9H); 1.40-1.58 (br m, 2H); 1.61-1.81 (m, 2H); 2.03-2.19 (br d, 2H); 2.23-2.40 (br t, 2H); 454.12 2.62-2.87 (br m, 4H); 3.61 (s, 2H); 7.42 (d, N OH J=8.08 Hz, 1H); 7.48 (d, J=8.26 Hz, 2H); 8.02 (d, J1=7.94 Hz J2=1.72 Hz, 1H); 8.10 (d, J=8.20 Hz, 2H); 8.20 (d, J=1.68 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD+D2O; 200.13 MHz ; d ppm) 1.29 (s, 9H); 1.45 (d, J=6.02 Hz, 6H); 1.50-1.63 (br d, 2H); 2.06-2.21 (br d, 2H); 2.28-2.44 (br t, 2H); 2.63-2.79 (br d, 2H); 544.15 N OH 3.35 (s, 3H); 3.44-3.62 (two singlets merged in triplet, 8H); 4.73 (septate, J=6.08 Hz, 1H); 7.08 (d, J=8.84 Hz, 1H); 7.48 (d, J=8.16 Hz, 2H); 8.02-8.13 (m, 3H); 8.22 (d, J=2.10 Hz, 1H); Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm) 0.85 (t, J=7.32 Hz, 3H); 1.26 (s, 9H); 1.43 (d, J=6.02 Hz, 6H); 1.49-1.61 (m, 4H); 2.03-2.20 (br d, 2H); 2.20-2.36 (br t, 2H); 2.70-2.86 (br 484.16 d, 2H); 3.60 (s, 2H); 4.74 (pentate, J=5.92 Hz, 1H); 7.09 (d, J=8.74 Hz, 1H); 7.47 (d, J=8.16 Hz, 2H); 8.03-8.13 (m, 3H); 8.23 (d, J=2.10 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 200.13 MHz ; d ppm) Cl 3 3 O 1.26 (s, 9H); 1.45 (d, J=6.04 Hz, 6H); 1.49- 496.12 1.62 (br d, 2H); 2.03-2.18 (br d, 2H); 2.23- N OH 2.39 (br m, 4H); 2.71-2.83 (br m, 2H); 3.62 (s, 2H); 4.72 (pentate, J=6.10 Hz, 1H); 4.95- .01 (br s, 1H); 5.01-5.10 (br d, 1H); 5.66- Ex. MS Structure NMR data No. (ES+) .90 (m, 1H); 7.06 (d, J=8.90 Hz, 1H); 7.48 (d, J=8.24 Hz, 2H); 8.01-8.13 (m, 3H); 8.22 (d, J=2.14 Hz, 1H); Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 200.13 MHz ; d ppm) 1.28 (s, 9H); 1.50-1.69 (br m, 2H); 2.01-2.18 (br d, 2H); 2.23-2.42 (br t, 2H); 2.73-2.87 (br d, 2H); 3. 00 (s, 2H); 3.61 (s, 2H); 7.12-7.27 565.12 N OH (m, 2H); 7.42-7.53 (br m, 7H); 7.55 (d, J=8.04 Hz, 1H); 7.63 (dt, J1=7.68 Hz, J2=1.82 Hz, 1H); 8.07-8.19 (m, 3H); 8.34 (d, J=1.64 Hz, 1H); 8.38-8.44 (br d, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD+TFA; 500.13 MHz ; d ppm) 1.42 (s, 9H); 1.84-1.94 (br t, 2H); 2.33-2.40 (br d, 2H); 2.87 (s, 2H); 2.94-3.02 (br t, 2H); 3.57-3.63 (br d, 2H); 3.80 (s, 3H); OH 4.30 (s, 3H); 6.83 (d, J=8.50 Hz, 2H); 7.01 594.12 (d, J=8.50 Hz, 2H); 7.44-7.50 (m, 1H); 7.50- 7.54 (m, 3H); 7.56 (d, J=8.10 Hz, 2H); 7.60 (d, J=8.00 Hz, 1H); 8.17 (dd, J1=8.05 Hz, J =1.40 Hz, 1H); 8.23 (d. J=8.15 Hz, 2H); 8.35 (d, J=1.40 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 400.13 MHz ; d ppm) 1.18 (s, 9H); 1.42-1.52 (br t, 2H); 1.98 (d, J=13.14 Hz, 2H); 2.18-2.28 (br t, 2H); 2.68- N OH 582.08 2.78 (s merged in m, 4H); 3.52 (s, 2H); 6.83 (t, J=8.61 Hz, 2H); 7.00-7.07 (m, 2H); 7.34- 7.45 (m, 7H); 7.47 (d, J=8.01 Hz, 1H); 8.03 (d, J=7.99 Hz, 2H); 8.07 (d, J=8.58 Hz, 1H); 8.26 (s, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD+TFA; 400.13 MHz ; 2 d ppm) 1.25-1.55 (s merged in m, 15H); 1.78- 1.97 (m, 6H); 2.27 (d, J=14.32 Hz, 2H); 2.81- 2.91 (s merged in m, 4H); 3.07-3.16 (br t, 600.12 N OH 1H); 3.49-3.56 (br d, 2H); 3.77 (s, 3H); 4.23 (s, 2H); 6.79 (d, J=8.37 Hz, 2H); 7.48 (d, J=8.17 Hz, 1H); 7.54 (d, J=8.03 Hz, 2H); 8.05 (d, J=8.03 Hz, 1H); 8.19-8.25 (s merged in d, 3H) Two protons are merged between 6.94-7.03 Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (Pyridine-d5; 400.13 MHz ; d ppm) 1.01 (t, J=7.38 Hz, 3H); 1.17 (s, 9H); 1.27- 1.43 (br m, 5H); 1.60-1.71 (br m, 3H) 1.71- 508.07 1.80 (br m, 5H); 1.80-1.86 (br d, 2H); 2.42- 54 N OH 2.52 (br t, 2H); 2.78-2.87 (br d, 2H); 3.03- 3.12 (br t, 1H); 3.53 (s, 2H); 7.47 (d, J=8.13 Hz, 1H); 7.65 (d, J=7.92 Hz, 2H); 8.14 (d, J=8.10 Hz, 1H); 8.32 (s, 1H); 8.39 (d, J=8.00 Hz, 2H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl +CD OD; 500.13 MHz ; d ppm) 1.26 (s, 9H); 1.53-1.61 (br t, 2H); 2.05-2.12 (br d, 2H); 2.22-2.29 (br t, 2H); 2.76-2.83 (br 564.12 d, 2H); 2.84 (s, 2H); 3.58 (s, 2H); 7.13-7.20 N OH (m, 3H); 7.20-7.25 (m, 2H); 7.43-7.53 (m, 7H); 7.56 (d, J=8.00 Hz, 1H); 8.11 (d, J=8.05 Hz, 2H); 8.16 (dd, J1=7.95 Hz, J2=1.45 Hz, 1H); 8.34 (d, J=1.30 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (Pyridine-d5; 400.13 MHz ; d ppm) 1.18 (s, 9H); 1.27-1.40 (br m, 5H); 1.63-1.71 (br d, 1H); 1.71-1.87 (br m, 4H); 1.91-2.12 (br t, 2H); 2.48-2.58 (br t, 4H); 2.82-2.92 (br N OH 571.15 d, 2H); 3.03-3.12 (br t, 1H); 3.39 (s, 2H); 3.53 ON (s, 2H); 7.04-7.10 (m, 1H); 7.35 (d, J=7.71 Hz, 1H); 7.47 (d, J=8.17 Hz, 1H); 7.52 (t, J=7.63 Hz, 1H); 7.62 (d, J=7.95 Hz, 2H); 8.15 (d, J=7.19 Hz, 1H); 8.32 (d, J=1.12 Hz, 1H); 8.37 (d, J=8.00 Hz, 2H); 8.65 (d, J=3.80 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 400.13 MHz ; d ppm) 1.26 (s, 9H); 1.45 (d, J=6.00 Hz, 6H); 1.53- 1.61 (m, 2H); 2.10-2.17 (br d, 2H); 2.35 (t, N OH 500.12 J=10.90 Hz, 2H); 2.72-2.81 (br d, 2H); 3.31 (s, 3H); 3.40 (s, 2H); 3.62 (s, 2H); 4.75 (septate, J=6.10 Hz, 1H); 7.10 (d, J=8.85 Hz, 1H); 7.48 (d, J=8.20 Hz, 2H); 8.06-8.12 (m, 3H); 8.23 (d, J=1.95 Hz, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (Pyridine-d ; 500.13 MHz ; d ppm) 1.15 (s, 9H); 1.77 (t, J=10.85 Hz, 2H); 2.40- 2.47 (br m, 4H); 2.84-2.87 (br d, 2H); 3.04 (s, 2H); 3.53 (s, 2H); 7.18-7.20 (br m,1H); 7.45- 565.11 7.60 (br m ,6H); 7.64-7.68 (br m, 3H); 8.20 (dd, J =7.95 Hz, J = 1.7 Hz, 1H); 8.41-8.45 N (br m, 3H); 8.63 (dd, J1=4.75 Hz, J2= 1.55 Hz, 1H); 8.83 (d, J=1.75 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.19 (t, J=7.05 Hz, 2 3H); 1.29 (s, 9H); 1.53-1.62 (br t, 2H); 2.00- 2.10 (m, 1H); 2.10-2.16 (br d, 2H); 2.36 (t, J=10.85 Hz, 2H); 2.71 (d, J=7.25 Hz, 2H); N OH 556.18 2.73-2.80 (br d, 2H); 3.48 (s, 2H); 3.53 (q, ON O J=7.05 Hz, 2H); 3.55-3.58 (br s, 4H); 3.62 (s, 2H); 7.39 (d, J=8.00 Hz, 1H); 7.49 (d, J=8.05 Hz, 2H); 8.02 (d, J=7.95 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H); 8.21 (d, J=1.10 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 400.13 MHz ; d ppm) NH 0.97 (d, J=6.64 Hz, 6H); 1.10 (d, J=6.08 Hz, 6H); 1.27 (s, 9H); 1.56-1.66 (br m, 2H); 1.99- 2.08 (m, 1H); 2.07-2.14 (br d, 2H); 2.30-2.39 N OH (br t, 2H); 2.71 (d, J=7.20 Hz, 2H); 2.73-2.80 526.18 (br d, 2H); 3.38 (pentate, J=1.64 Hz, 1H); ON O 3.44 (s, 2H); 3.61 (s, 2H); 7.38 (d, J=8.00 Hz, 1H); 7.48 (d, J=8.24 Hz, 2H); 8.02 (dd, J1=7.92 Hz, J2=1.72 Hz, 1H); 8.10 (d, J=8.24 Hz, 2H); 8.21 (d, J=1.68 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.27 (s, 9H); 1.44- 1.50 (br m, 2H); 1.57-1.69 (br m, 8H); 1.99- 2.07 (m, 1H); 2.07-2.13 (br d, 2H); 2.32-2.39 OH (br t, 2H); 2.70 (d, J=7.20 Hz, 2H); 2.72-2.79 552.17 (br m, 2H); 3.40 (s, 2H); 3.62 (s, 2H); 3.81- 3.86 (br m, 1H); 7.37 (d, J=8.00 Hz, 1H); 7.48 (d, J=8.20 Hz, 2H); 8.01 (dd, J =7.95 Hz, J2=1.65 Hz, 1H); 8.10 (d, J=8.15 Hz, 2H); 8.21 (d, J=1.55 Hz, 1H) Three exchangeable protons Ex. MS Structure NMR data No. (ES+) as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.97 (d, J=6.60 Hz, 6H); 1.28 (s, 9H); 1.56- 1.64 (br m, 2H); 2.05 (septate, J=6.75 Hz, 1H); 2.09-2.16 (br d, 2H); 2.33-2.42 (br t, 2H); 2.71 (d, J=7.25 Hz, 2H); 2.75-2.82 (br d, 550.11 62 OH 2H); 3.14 (s, 2H); 3.62 (s, 2H); 6.81 (d, J=3.35 Hz, 1H); 6.89 (t, J=3.65 Hz, 1H); 7.10 (d, J=5.25 Hz, 1H); 7.39 (d, J=8.00 Hz, 1H); 7.48 (d, J=8.10 Hz, 2H); 8.02 (dd, J1=7.95 Hz, J2=1.45 Hz, 1H); 8.10 (d, J=8.05 Hz, 2H); 8.20 (d, J=1.30 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3 +CD3OD; 500.13 MHz ; d ppm) 0.01-0.06 (br m, 2H); 0.38-0.44 (br m, 2H); 0.64-0.73 (br m, 1H); 0.97 (d, J=6.65 Hz, O 6H); 1.28 (s, 9H); 1.44 (d, J=6.70 Hz, 2H); 1.53-1.62 (br t, 2H); 2.05 (septate, J= 6.85 508.18 Hz, 1H); 2.17-2.24 (br d, 2H); 2.27-2.37 (br t, 2H); 2.71 (d, J=7.20 Hz, 2H); 2.78-2.85 (br d, 2H); 3.63 (s, 2H); 7.40 (d, J=6.50 Hz, 1H); 7.49 (d, J=8.15 Hz, 2H); 8.02 (dd, J1=7.90 Hz, J2=1.65 Hz, 1H); 8.10 (d, J=8.10 Hz, 2H); 8.20 (d, J=1.60 Hz, 1H) Three exchangeable protons as free form PMR : (CDCl +CD OD+D O; 500.13 MHz ; 3 3 2 d ppm) 0.97 (d, J=6.65 Hz, 6H); 1.45-1.53 (br dt, 2H); 1.77 (t, J=7.35 Hz, 2H); 2.04 (septate, J=6.75 Hz, 1H); 2.10-2.16 (br d, 567.16 2H); 2.27 (t, J=10.70 Hz, 2H); 2.61 (t, J=7.30 Hz, 2H); 2.66-2.75 (br d merged with m, 8H); 3.57 (s, 2H); 3.74-3.80 (br t, 4H); 7.36 (d, J=8.00 Hz, 1H); 7.46 (d, J=8.05 Hz, 2H); 8.01 (dd, J1=7.94 Hz, J2=1.55 Hz, 1H); 8.10 (d, J=8.15 Hz, 2H); 8.21 (d, J=1.55 Hz, 1H) One exchangeable protons as t-butyl amine salt PMR : (CDCl3; 400.13 MHz ; d ppm) 0.96 (d, N OH J=6.64 Hz, 6H); 1.21 (s, 9H); 1.32-1.43 (br ON 579.18 m, 4H); 1.60-1.76 (br m, 8H); 2.04 (septate, NH J=6.84 Hz, 1H); 2.14-2.24 (br m, 8H); 2.61- 2.68 (br m, 2H); 2.70 (d, J=7.20 Hz, 2H); 2.72-2.79 (br m, 2H); 3.58 (s, 2H); 7.36 (d, Ex. MS Structure NMR data No. (ES+) J=8.00 Hz, 1H); 7.44 (d, J=8.24 Hz, 2H); 8.01 (dd, J1=7.96 Hz, J2=1.76 Hz, 1H); 8.08 (d, J=8.28 Hz, 2H); 8.20 (d, J=1.72 Hz, 1H) Three exchangeable protons as t-butyl amine salt PMR : (CDCl3; 400.13 MHz ; d ppm) 0.96 (d, J=6.64 Hz, 6H); 1.20 (s, 9H); 1.30-1.41 (br m, 4H); 1.59-1.70 (br m, 2H); 1.83-1.91 (br s, 6H); 1.98-2.09 (m, 1H); 2.09-2.20 (br m, 6H); 565.23 2.70 (d, J=7.20 Hz, 2H); 2.71-2.83 (m, 4H); 3.57 (s, 2H); 7.36 (d, J=8.00 Hz, 1H); 7.43 (d, J=8.20 Hz, 2H); 8.01 (dd, J1=7.92 Hz, J =1.68 Hz, 1H); 8.07 (d, J=8.20 Hz, 2H); 8.21 (d, J=1.64 Hz, 1H) Three exchangeable protons Biological activity Some of the representative compounds of the present invention were tested for in- vitro and in-vivo efficacy as mentioned below. a) 35S-GTP γS Binding Assay GTP- γ- S binding was performed using 5 µg protein of cell membranes suspended in 50 mM tris-HCl pH 7.5 containing 10 mM MgCl , 100 mM NaCl and 10 µM GDP. The radioligand was 0.025 nM [ S] GTP- γ-S and non specific binding determined in the presence of 10 µM non-radioactive GTP- γ-S. Agonists of S1P receptors can be discriminated in the [ S] GTP- γ-S binding assay. S1P and receptor agonists enhance the specific binding whereas inverse agonists reduce it. The maximal stimulation elicited by S1P was taken as a reference to define full or partial agonism and calculate the intrinsic activity (i.a.) of compounds.
Typical results shown in Table 1a indicate that compounds of the invention are able to activate S1P1 receptors with a potency similar to that of S1P itself (i.e. with full intrinsic activity and at nanomolar concentrations) without affecting significantly S1P2 and S1P3 receptors.
Table 1b summarizes the half maximal effective concentration (EC50) for the examples of the present application.
Furthermore, we settled a binding assay on HEK293-EDG-1 cells on these membranes using [3H]dihydroS1P. By Scatchard analysis we identified one binding site for [3H]dihydroS1P. Both S1P and dihydroS1P (an S1P biometabolite) compete with [3H]dihydroS1P on transfected HEK293 cells with an IC50 closed to 5 ± nM and a maximum binding capacity Bmax of 13 pmol/mg of protein. b) Assessment of lymphopenia Lymphopenia was assessed in vivo. Experiments were done in non-fasted/fasted Swiss mice and/or: Sprague Dawley rats, Wistar rats, Beagle dogs, Cynomolgus monkeys.
Compounds were administered orally in suspension in carboxymethyl-cellulose 0.5-1% in water (W/V). Blood was taken on anesthetized/non anaesthetized animal (4% isoflurane) and samples collected in EDTA-containing vacuum tubes from 1h30 to 72 hours post administration for lymphopenia measurement.
After 10 minutes stirring, cells were counted using ABC Vet haemocytometer (Scil vet animal Care) for rodent and dog or ADVIA 120 hematology analyzer for monkeys.
Pharmacodynamic effect was measured by the decrease in circulating lymphocytes by test item treatment in comparison with haematological parameters of control animals or versus predosing in the same animals. c) Evaluation of activityfor hERG blockade liability HEK293 cells were stably transfected with the human hERG receptor gene. Binding assays were performed using 5 µg of cell membranes expressing hERG channel resuspended in 10mM Hepes pH 7.4, 135 mM NaCl, 60 mM DL-Aspartic Acid Potassium, 1 mM EGTA, 0.8 mM MgCl , 10 mM (D+) Glucose, 0.01 % BSA, in a final volume of 200 µL.
For [ H] Dofetilide binding, the incubation volume was 200 µL and incubation was performed 60 minutes at room temperature under continuous stirring. Non specific binding was estimated in the presence of 1 µM Astemizole. The reaction was terminated by filtration through Durapore BV 1.2 µm filters pre-soaked in 3 % polyethyleneimine 10 minutes at room temperature. Filters were rinsed 2 times with 250 µL of ice cold 25 mM Tris-HCl pH 7.4 buffer. The filter-bound radioactivity was measured in a liquid scintillation counter with 50 µL of scintillation fluid. [ H] Dofetilide was used at concentrations in the range of 5 nM.
The hERG binding investigated by use of [ H] Dofetilide gives a Bmax = 3.09 pmoles/mg protein and a Kd = 4.24 nM.
No binding was detectable in wild type HEK293 cell membranes.
Tables 1 (Table 1a and 1b) and 2 show the results of the in vitro and the in vivo tests on some of the representative compounds of the present invention.
Table 1: in vitro evaluation Table 1a: EC50 (nM) hERG Structure (dofetilide) No. EDG1 EDG3 EDG5 Ki (µM) <1 >1000 >1000 >10 N OH N OH <1 - - >10 <1 581 >1000 >10 <1 >1000 >1000 >10 N OH <1 610 - >10 N OH O N O <1 198 >1000 >10 N OH <1 >1000 >1000 >10 EC50 (nM) hERG Structure (dofetilide) EDG1 EDG3 EDG5 Ki (µM) <1 >1000 >1000 >10 N OH <1 >1000 >1000 >10 N OH N OH <1 >1000 >1000 >10 Table 1b : EDG1 EDG1 EDG1 EDG1 EDG1 Ex Ex Ex Ex Ex EC50 EC50 EC50 EC50 EC50 1 <1 2 <1 4 <1 5 <1 6 <1 7 <1 8 <1 9 <1 10 <1 11 <1 12 <1 13 <1 14 <1 15 <1 16 <1 17 <1 18 <1 19 <1 20 <1 21 <1 22 <1 23 <10 24 <10 25 <1 26 <1 27 <1 28 <1 29 <1 30 <1 31 <10 32 <1 33 <1 34 <1 35 <1 36 <10 37 <1 38 <10 39 <10 40 <1 41 <1 42 <1 43 <1 44 <10 45 <10 46 <1 47 <1 48 <10 49 <1 50 <1 51 <1 52 <1 53 <1 54 <1 55 <1 56 <1 57 <10 58 <1 59 <1 60 <1 61 <1 62 <1 63 <1 64 <10 65 <10 66 <10 Table 2: in vivo evaluation Lymphopenia in rats Ex. No. Structure % lymphopenia at given dose at Species 24hrs N OH 76% (0.3mpk) SD F 75% (0.3 mpk) W F N OH 66% (0.3 mpk) W F N OH 72% (0.3 mpk) W M O N O 69% (0.3mpk) SD F N OH ON OH W: Wistar SD: Sprague-Dawley M: male F: female The results above show that the compounds of the present invention are S1P agonists and have high affinity for human EDG1 receptors (EC50 ≤ about 2 nM). More preferred compounds of the invention have EC50 less than 1 nM. The compounds of the present invention possess about 500 fold selectivity for EDG1 receptors over EDG3 receptor.
Furthermore, the compounds of present invention have about 400 fold selectivity for EDG1 receptor over hERG channel and hence are expected to demonstrate a better side effect profile.
The preferred compounds of the present invention were found to exhibit lymphopenic activity in-vivo when administered orally to animal models. More preferably, the compounds of the invention exhibited lymphopenic activity of more than 50% at 8 hours and did not bind to hERG channel, even at a concentration as high as 5µM.
Most preferably, the compounds of the invention which possessed EC50 of less than 1nM, have >1000 fold selectivity for EDG1 receptor over EDG3, exhibited in-vivo lymphopenic activity of more than 50% at 24 hours and did not bind to hERG even at a concentration as high as 10µM.
Comparative examples: The table below shows that the WO2008/152149 monosubstituted carboxylate derivatives are poorly active in vitro as agonist on the human EDG1 receptor and ineffective in producing lymphopenia in rat model.
Lymphopenia in rats EDG1 % lymphopenia at 1 Comparative compounds EC50 mpk/p.o dose (nM) 8 Hrs 24 Hrs N OH 1 11.7-19.8 -54% O N O Example XXVIII of WO2008/152149 N OH 2 57.2 -25% -101% O N O Example XXXI of WO2008/152149 N COOH CH N 3 56.6 -58% -24% Example XIL of WO2008/152149 N OH 4 13.9 -57% O N O Example XXXVI of WO2008/152149 Moreover, preferred compounds of the present invention also display an outstanding bioavailability. Comparison with a compound of WO2003105771 is shown in the following table: Pharmacokinetic parameters in Swiss mice after oral administration (1 mg/kg p.o.) Structure (n=4) Cmax AUC(0-48h) (ng/mL) (ng/mL*h) Comparative compound 5 495 4530 Example 1 of WO2003105771 Example 3 798 13111 N OH Example 14 N 843 9241 O N O It appears from the in vivo ED50 values below that the representative disubstituted monocarboxylate derivatives of the present invention exhibit improved in vivo lymphopenia activity over their corresponding dicarboxylate counterparts disclosed in : ED50 (EDG1) (In mice) Example 8 O 0.1 mg/kg CO H Comparative 0.4 mg/kg example 6 F N OH ON O OH Example 3 of Example 3 0.2 mg/kg CO H Example 14 0.2 mg/kg N OH O N O Comparative 1.8 mg/kg example 7 N OH ON O OH Example 1 of Example 10 0.2 mg/kg N OH O N O Comparative 10 mg/kg example 8 N OH ON O OH Example 37 of The compounds of the invention show a better in vivo activity profile over their corresponding counterparts of , as evidenced below : ED50 (EDG1) Compound of the 40% at 1 mg/kg invention ON O OH Comparative Inactive at 1 example 9 mg/kg Example 7 of In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

Claims (23)

1. A compound of formula (I): N R2 COOH wherein: Ar is an aryl group optionally substituted by one or more identical or different group(s) selected from halogen, alkyl, cycloalkyl, -Oalkyl, aryl wherein the alkyl, cycloalkyl, -Oalkyl, aryl may be further substituted with halogen, OH, Oalkyl, CN, NH , NHalkyl, N(alkyl) or alkyl; R1 represents –X-(Y) Where -X- is selected from –alkyl-, -alkenyl-, -alkynyl-, -aryl-, -alkylaryl-, Each Y, identical or different is selected from H, OH, halogen, -Oalkyl, -Oalkylaryl, -OalkylOalkyl, -Oaryl, heteroaryl, -Oaryl(Oalkyl), -Ocycloalkyl, -cycloalkyl, heterocyclyl; n is 1 to 3; R2 is selected from H, alkyl; or one of its stereoisomers, salts or esters thereof.
2. The compound according to claim 1, wherein Ar is a disubstituted phenyl group.
3. The compound according to claim 1 or 2 of formula (II): COOH (II) wherein : R1 is defined as in claim 1 ; R3 is selected from halogen, aryl, cycloalkyl, alkyl, and -Oalkyl ; Hal represents a halogen atom.
4. The compound according to any one of the preceding claims, wherein R1 is selected from: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secondarybutyl, tertiary butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, methoxymethyl, ethoxymethyl, methoxyethyl, vinyl, allyl, methoxyethoxymethyl, ethoxyethoxymethyl, ethoxyethoxyethyl, Phenyl, benzyl, benzyloxymethyl, benzyloxyethyl, -CH -[Ph(o-F)], -CH -[Ph(m-F)], -CH -[Ph(p-F)], -CH -[Ph(o-OMe)], -CH -[Ph(m-OMe)], or 2 2 2 2 2 -CH -[Ph(p-OMe)], methoxybutyl, methoxyethoxymethyl, methoxyethoxyethyl, -CH -[Ph(o,o- F)], -CH -[Ph(m-CF)], -CH-furyl, -CH-pyridyl, (2-methoxy-phenoxy)-ethyl, 4-methoxy- 2 2 3 2 2 benzyl, isopropoxy methyl, cyclopentyloxymethyl, thiophenylmethyl, cyclopropylmethyl, 2-morpholinyl-ethyl, 3-piperidinyl-propyl, 3-pyrrolidinyl-propyl.
5. The compound according to any one of the preceding claims, wherein R2 is H.
6. The compound according to any one of the preceding claims, wherein R3 is selected from phenyl, cyclohexyl, cyclopentyl, isobutyl, , isopropoxy.
7. The compound according to any one of the preceding claims which is selected from: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} hydroxymethylpiperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl} methoxymethylpiperidinecarboxylic acid 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidine carboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} hydroxymethylpiperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine- 4-carboxylic acid 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine carboxylic acid 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- butyl)-piperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy- ethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy- phenoxy)-ethyl]-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine- 4-carboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methoxymethyl-piperidinecarboxylic acid 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy- ethoxymethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopentyloxymethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophen ylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopropylmethyl-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-morpholin yl-ethyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-piperidinyl- propyl)-piperidinecarboxylic acid 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(3-pyrrolidinyl- propyl)-piperidinecarboxylic acid and their pharmaceutically acceptable salts, or esters thereof.
8. The compound according to any one of the preceding claims which is selected from: 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, sodium salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, arginine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid, potassium salt 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methylpiperidinecarboxylic acid 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}methylpiperidine carboxylic acid 1-{4-[5-(3-chlorocyclopentylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid, tert-butylamine salt 1-{4-[5-(3-chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]benzyl} methoxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}ethylpiperidine carboxylic acid tert-butylamine salt 4-allyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}piperidine carboxylic acidtert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}propylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl} hydroxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]oxadiazolyl]-benzyl} methoxymethylpiperidinecarboxylic acid tert-butylamine salt 4-Allyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}piperidine carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}propylpiperidine carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butylamine salt 4-Benzyloxymethyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]- benzyl}piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl} hydroxymethylpiperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}phenylpiperidine- 4-carboxylic acid tert-butylamine salt 4-Benzyl{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}-piperidine- 4-carboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-fluoro-benzyl)- piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}(2-methoxy- benzyl)-piperidinecarboxylic acid tert-butylamine salt 1-{4-[5-(2-chlorobiphenylyl)-[1,2,4]-oxadiazolyl]benzyl}ethoxymethylpiperidine- 4-carboxylic acid tert-butylamine salt 1-{4-[5-(2-Chlorobiphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}ethylpiperidine carboxylic acid tert-butylamine salt, 1-{4-[5-(4-Isobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- butyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-chloroisobutylphenyl)-[1,2,4]-oxadiazolyl]benzyl}(2- methoxyethoxymethyl)piperidinecarboxylic acid potassium salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-phenoxy- ethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2,6-difluoro- benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isobutyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(3-trifluoro methyl-benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]oxadiazolyl]-benzyl}furanylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}[2-(2-methoxy- phenoxy)-ethyl]-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(4-tert-Butylchloro-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloropropyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}methyl-piperidine- 4-carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-methoxy- ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid tert-butyl amine salt 4-Allyl{4-[5-(3-chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-fluoro-benzyl)- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}(4-methoxy- benzyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexylphenyl)-[1,2,4]-oxadiazolyl]-benzyl}ethyl- piperidinecarboxylic acid tert-butyl amine salt 4-Benzyl{4-[5-(2-chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}-piperidine carboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chlorocyclohexyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridin ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisopropoxy-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} methoxymethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(2-Chloro-biphenylyl)-[1,2,4]-oxadiazolyl]-benzyl}pyridinylmethyl- piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}(2-ethoxy- ethoxymethyl)-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}isopropoxy methyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopentyloxymethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl}thiophen ylmethyl-piperidinecarboxylic acid tert-butyl amine salt 1-{4-[5-(3-Chloroisobutyl-phenyl)-[1,2,4]-oxadiazolyl]-benzyl} cyclopropylmethyl-piperidinecarboxylic acid tert-butyl amine salt, or one of their stereoisomers.
9. A process of preparation of a compound according to any one of the preceding claims comprising saponifying a compound of formula (III) N R2 COOAlk (III) where Ar, R2, R1 are defined as any one of the preceding claims and Alk represents a C1- C6 alkyl group, optionally followed by forming the desired addition salt.
10. The process according to claim 9 which further comprises the step of preparing the compound of formula (III) by coupling a compound of formula (IV): N R2 (IV) with a corresponding compound of formula (V): COOAlk where Ar, R2, R1 are defined as in any one of claims 1 to 8, Alk is defined as in claim 9 and LG is a leaving group
11. The process according to claim 10 further comprising the step of preparing the compound of formula (IV) wherein LG is a halide or mesylate, by converting a compound of formula (VI): N R2 (VI) where Ar and R2 are defined as in any one of claims 1 to 8 into the desired halide or mesylate.
12. A process of preparation of a compound according to any one of claims 1 to 8 comprising reacting a compound of formula (VII): N R2 (VII) with a compound of formula (VIII) COOR (VIII) where Ar, R2, R1 are defined as in any one of claims 1 to 8, and R may be alkyl, optionally followed by forming the desired addition salt.
13. The process according to claim 12 further comprising the step of preparing the compound of formula (VII) by oxidizing a compound of formula (VI): N R2 (VI) where Ar and R2 are defined as in any one of claims 1 to 8.
14. The process according to claim 11 or 13 further comprising: (a) preparing the compound of formula (VI) R2 is H by reacting a compound of formula (IX): (IX) where Ar is defined as in any one of claims 1 to 8, with N-hydroxyhydroxymethylbenzamidine, optionally in the presence of one or more of activating and/or coupling agent, optionally followed by (b) oxidizing the obtained compound of formula (VI) (wherein R2 is H) followed by its reaction with alkylmagnesiumhalide.
15. The process according to any one of claims 9 to 14 further comprising the additional step of isolating the obtained compound.
16. A compound prepared by the process of any one of claims 9 to 15.
17. The compound according to any one of claims 1 to 8 and 16 for use in the treatment and/or prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis, atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired vascular integrity, cancer, or other disorders.
18. A use of a compound according to any one of claims 1 to 8 and 16 in the manufacture of a medicament for the treatment and/or prevention of transplant rejection, tissue graft rejection, immune disorders auto-immune diseases, autoimmune uveitis, ischemia, inflammatory and chronic inflammatory conditions that include rheumatoid arthritis, asthma, pollinosis, psoriasis, Alzheimer’s disease, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, sepsis, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases, diabetes mellitus, glomerulonephritis, atherosclerosis, multiorgan failure, pneumonia, ischemia reperfusion injury, chronic obstructive pulmonary disease, infection associated with inflammation, viral inflammation, hepatitis, chronic bronchitis, granulomatous disease, as well as disorders related to impaired vascular integrity, cancer, or other disorders.
19. A combination comprising a compound according to any one of claims 1 to 8 and 16 with an immunosuppressant including adrenocortical steroids, cyclosporine, azathioprine, methotrexate, calcineurin inhibitors, IL-2 receptor blocking antibodies, T-cell and other immune cell depleting antibodies, anti-TNF, mycophenolate, mTOR inhibitors.
20. A compound as claimed in claim 1 or claim 16, substantially as herein described with reference to any example thereof.
21. A process as claimed in claim 9 or claim 12, substantially as herein described with reference to any example thereof.
22. A use as claimed in claim 18, substantially as herein described with reference to any example thereof.
23. A combination as claimed in claim 19, substantially as herein described with reference to any example thereof.
NZ617500A 2011-04-12 2012-04-10 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists NZ617500B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305433.2 2011-04-12
EP11305433A EP2511275A1 (en) 2011-04-12 2011-04-12 Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
PCT/EP2012/056470 WO2012140020A1 (en) 2011-04-12 2012-04-10 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists

Publications (2)

Publication Number Publication Date
NZ617500A NZ617500A (en) 2016-03-31
NZ617500B2 true NZ617500B2 (en) 2016-07-01

Family

ID=

Similar Documents

Publication Publication Date Title
CA3076150C (en) Selective p2x3 modulators
ES2603262T3 (en) Substituted aminoindane-carboxylic and aminotetralin-carboxylic acids and their use
EP2014653A1 (en) Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US5877191A (en) Phenyl spiroethercycloalkyl tachykinin receptor antagonists
WO2006123725A1 (en) Pyrrolidine derivative or salt thereof
JP2005531506A (en) Aminoalkylphosphonates and related compounds as agonists of EDG receptors
EP2194044A1 (en) Quinolone derivative
JP2008517897A (en) Novel dicarboxylic acid derivatives
JP5296073B2 (en) Benzoyl-piperidine derivatives as dual modulators of 5-HT2A and D3 receptors
TW201141856A (en) (R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors
TW202304864A (en) 1,3-substituted cyclobutyl derivatives and uses thereof
EP2697219B1 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
JP2011528346A (en) Novel compounds active as muscarinic receptor antagonists
WO1992017440A1 (en) Tricyclic compound
JP2006509793A (en) Isophthalic acid derivatives
WO2005073183A1 (en) Aryl sulfide derivative
WO2012065527A1 (en) Compouds and uses as l-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof
CN110372571A (en) A kind of 2- (2,2- diaryl ethyl)-Cycloamine derivative or salt and synthesis and application and composition
JP2023035972A (en) Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
NZ617500B2 (en) Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
WO2014142056A1 (en) Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
WO1998017660A1 (en) Phenyl spiroethercycloalkyl tachykinin receptor antagonists
JP2008001596A (en) Sodium channel inhibitor
WO2005080385A1 (en) Indanol derivative
EA046249B1 (en) LOW MOLECULAR FXR AGONISTS, THEIR PRODUCTION METHOD AND APPLICATION